{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:44:29Z","timestamp":1793382269840,"version":"4.5.0"},"reference-count":393,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gouvernement du Canada | Canadian Institutes of Health Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02768-4","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:56:39Z","timestamp":1780674999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation"],"prefix":"10.1038","volume":"11","author":[{"given":"Alyanna M.","family":"Popatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Sharanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-3381","authenticated-orcid":false,"given":"Arezu","family":"Jahani-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2768_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","volume":"9","author":"M He","year":"2024","unstructured":"He, M., Zhou, X. & Wang, X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct. Target. Ther. 9, 194 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2768_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.gastro.2019.08.060","volume":"158","author":"X Verhelst","year":"2020","unstructured":"Verhelst, X. et al. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology 158, 95\u2013110 (2020).","journal-title":"Gastroenterology"},{"key":"2768_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2018.12.002","volume":"162","author":"M Hu","year":"2019","unstructured":"Hu, M. et al. Glycan-based biomarkers for diagnosis of cancers and other diseases: past, present, and future. Prog. Mol. Biol. Transl. Sci. 162, 1\u201324 (2019).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"2768_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/bs.accb.2016.07.001","volume":"73","author":"C Li","year":"2016","unstructured":"Li, C. & Wang, L. X. Endoglycosidases for the synthesis of polysaccharides and glycoconjugates. Adv. Carbohydr. Chem. Biochem. 73, 73\u2013116 (2016).","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"2768_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","volume":"27","author":"A Varki","year":"2017","unstructured":"Varki, A. Biological roles of glycans. Glycobiology 27, 3\u201349 (2017).","journal-title":"Glycobiology"},{"key":"2768_CR6","doi-asserted-by":"publisher","first-page":"e202451318","DOI":"10.1002\/eji.202451318","volume":"55","author":"E Rodriguez","year":"2025","unstructured":"Rodriguez, E. Tumor glycosylation: a main player in the modulation of immune responses. Eur. J. Immunol. 55, e202451318 (2025).","journal-title":"Eur. J. Immunol."},{"key":"2768_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s42004-020-00337-6","volume":"3","author":"MI Zol-Hanlon","year":"2020","unstructured":"Zol-Hanlon, M. I. & Schumann, B. Open questions in chemical glycobiology. Commun. Chem. 3, 102 (2020).","journal-title":"Commun. Chem."},{"key":"2768_CR8","unstructured":"Varki, A. et al. in Essentials of Glycobiology (eds Varki, A. et al.) (2022)."},{"key":"2768_CR9","doi-asserted-by":"publisher","first-page":"15603","DOI":"10.1021\/acs.chemrev.1c01032","volume":"122","author":"SS Shivatare","year":"2022","unstructured":"Shivatare, S. S., Shivatare, V. S. & Wong, C. H. Glycoconjugates: synthesis, functional studies, and therapeutic developments. Chem. Rev. 122, 15603\u201315671 (2022).","journal-title":"Chem. Rev."},{"key":"2768_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","volume":"15","author":"C Reily","year":"2019","unstructured":"Reily, C., Stewart, T. J., Renfrow, M. B. & Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol. 15, 346\u2013366 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"2768_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540\u2013555 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2768_CR12","doi-asserted-by":"publisher","first-page":"188464","DOI":"10.1016\/j.bbcan.2020.188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas, D., Rathinavel, A. K. & Radhakrishnan, P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim. Biophys. Acta Rev. Cancer 1875, 188464 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2768_CR13","doi-asserted-by":"crossref","unstructured":"Ideo, H., Tsuchida, A. & Takada, Y. Lectin-based approaches to analyze the role of glycans and their clinical application in disease. Int. J. Mol. Sci. 25, 10231 (2024).","DOI":"10.3390\/ijms251810231"},{"key":"2768_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaci.2023.09.003","volume":"153","author":"RC Hale","year":"2024","unstructured":"Hale, R. C., Morais, D., Chou, J. & Stowell, S. R. The role of glycosylation in clinical allergy and immunology. J. Allergy Clin. Immunol. 153, 55\u201366 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2768_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-016-0334-6","volume":"9","author":"WL Ho","year":"2016","unstructured":"Ho, W. L. et al. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J. Hematol. Oncol. 9, 100 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2768_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fonc.2014.00028","volume":"4","author":"I Hauselmann","year":"2014","unstructured":"Hauselmann, I. & Borsig, L. Altered tumor-cell glycosylation promotes metastasis. Front. Oncol. 4, 28 (2014).","journal-title":"Front. Oncol."},{"key":"2768_CR17","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-18-3870","volume":"26","author":"P Navarro","year":"2020","unstructured":"Navarro, P., Martinez-Bosch, N., Blidner, A. G. & Rabinovich, G. A. Impact of galectins in resistance to anticancer therapies. Clin. Cancer Res. 26, 6086\u20136101 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","volume":"22","author":"KV Marino","year":"2023","unstructured":"Marino, K. V., Cagnoni, A. J., Croci, D. O. & Rabinovich, G. A. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat. Rev. Drug Discov. 22, 295\u2013316 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2768_CR19","doi-asserted-by":"publisher","first-page":"1104625","DOI":"10.3389\/fimmu.2022.1104625","volume":"13","author":"DJ Laderach","year":"2022","unstructured":"Laderach, D. J. & Compagno, D. Inhibition of galectins in cancer: Biological challenges for their clinical application. Front. Immunol. 13, 1104625 (2022).","journal-title":"Front. Immunol."},{"key":"2768_CR20","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1017\/S1462399408000719","volume":"10","author":"RY Yang","year":"2008","unstructured":"Yang, R. Y., Rabinovich, G. A. & Liu, F. T. Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med. 10, e17 (2008).","journal-title":"Expert Rev. Mol. Med."},{"key":"2768_CR21","doi-asserted-by":"publisher","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","volume":"16","author":"I Camby","year":"2006","unstructured":"Camby, I., Le Mercier, M., Lefranc, F. & Kiss, R. Galectin-1: a small protein with major functions. Glycobiology 16, 137R\u2013157R (2006).","journal-title":"Glycobiology"},{"key":"2768_CR22","unstructured":"Taylor, M. E. et al. in Essentials of Glycobiology (eds Varki, A. et al.) 375\u2013386 (2022)."},{"key":"2768_CR23","doi-asserted-by":"crossref","unstructured":"Raposo, C. D., Canelas, A. B. & Barros, M. T. Human lectins, their carbohydrate affinities and where to find them. Biomolecules 11, 188 (2021).","DOI":"10.3390\/biom11020188"},{"key":"2768_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0304-4165(02)00317-3","volume":"1572","author":"N Dahms","year":"2002","unstructured":"Dahms, N. & Hancock, M. K. P-type lectins. Biochim. Biophys. Acta 1572, 317\u2013340 (2002).","journal-title":"Biochim. Biophys. Acta"},{"key":"2768_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41577-018-0004-8","volume":"18","author":"GD Brown","year":"2018","unstructured":"Brown, G. D., Willment, J. A. & Whitehead, L. C-type lectins in immunity and homeostasis. Nat. Rev. Immunol. 18, 374\u2013389 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2768_CR26","unstructured":"Angata, T., von Gunten, S., Schnaar, R. L. & Varki, A. in Essentials of Glycobiology (eds Varki, A. et al.) 475\u2013490 (2022)."},{"key":"2768_CR27","unstructured":"Dahms, N., Braulke, T. & Varki, A. in Essentials of Glycobiology (eds Varki, A. et al.) 443\u2013454 (2022)."},{"key":"2768_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10719-020-09942-y","volume":"37","author":"M Tsaneva","year":"2020","unstructured":"Tsaneva, M. & Van Damme, E. J. M. 130 years of plant lectin research. Glycoconj. J. 37, 533\u2013551 (2020).","journal-title":"Glycoconj. J."},{"key":"2768_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10719-021-10015-x","volume":"39","author":"EJM Van Damme","year":"2022","unstructured":"Van Damme, E. J. M. 35 years in plant lectin research: a journey from basic science to applications in agriculture and medicine. Glycoconj. J. 39, 83\u201397 (2022).","journal-title":"Glycoconj. J."},{"key":"2768_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.110827","volume":"134","author":"A Mishra","year":"2019","unstructured":"Mishra, A. et al. Structure-function and application of plant lectins in disease biology and immunity. Food Chem. Toxicol. 134, 110827 (2019).","journal-title":"Food Chem. Toxicol."},{"key":"2768_CR31","unstructured":"Cummings, R. D. et al. in Essentials of Glycobiology (eds Varki, A. et al.) 431\u2013442 (2022)."},{"key":"2768_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0076-6879(10)79013-3","volume":"479","author":"PK Grewal","year":"2010","unstructured":"Grewal, P. K. The Ashwell\u2013Morell receptor. Methods Enzymol. 479, 223\u2013241 (2010).","journal-title":"Methods Enzymol."},{"key":"2768_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s42485-022-00102-4","volume":"14","author":"A Radhakrishnan","year":"2023","unstructured":"Radhakrishnan, A., Chellapandian, H., Ramasamy, P. & Jeyachandran, S. Back2Basics: animal lectins: an insight into a highly versatile recognition protein. J. Proteins Proteom. 14, 43\u201359 (2023).","journal-title":"J. Proteins Proteom."},{"key":"2768_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00281-024-01010-z","volume":"46","author":"R Jacob","year":"2024","unstructured":"Jacob, R. & Gorek, L. S. Intracellular galectin interactions in health and disease. Semin. Immunopathol. 46, 4 (2024).","journal-title":"Semin. Immunopathol."},{"key":"2768_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clim.2011.09.011","volume":"142","author":"F Cedeno-Laurent","year":"2012","unstructured":"Cedeno-Laurent, F. & Dimitroff, C. J. Galectin-1 research in T cell immunity: past, present and future. Clin. Immunol. 142, 107\u2013116 (2012).","journal-title":"Clin. Immunol."},{"key":"2768_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00759-1","volume":"13","author":"N Zhang","year":"2025","unstructured":"Zhang, N. et al. Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy. Biomark. Res. 13, 49 (2025).","journal-title":"Biomark. Res."},{"key":"2768_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41577-022-00829-7","volume":"23","author":"FT Liu","year":"2023","unstructured":"Liu, F. T. & Stowell, S. R. The role of galectins in immunity and infection. Nat. Rev. Immunol. 23, 479\u2013494 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2768_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105400","volume":"299","author":"MF Troncoso","year":"2023","unstructured":"Troncoso, M. F. et al. The universe of galectin-binding partners and their functions in health and disease. J. Biol. Chem. 299, 105400 (2023).","journal-title":"J. Biol. Chem."},{"key":"2768_CR39","doi-asserted-by":"crossref","unstructured":"Zhao, Z. et al. Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization\/phase separation. Proc. Natl. Acad. Sci. USA 118, e2021074118 (2021).","DOI":"10.1073\/pnas.2021074118"},{"key":"2768_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/glycob\/cwq144","volume":"21","author":"LA Earl","year":"2011","unstructured":"Earl, L. A., Bi, S. & Baum, L. G. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology 21, 6\u201312 (2011).","journal-title":"Glycobiology"},{"key":"2768_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107577","volume":"300","author":"JI Quintana","year":"2024","unstructured":"Quintana, J. I. et al. Different roles of the heterodimer architecture of galectin-4 in selective recognition of oligosaccharides and lipopolysaccharides having ABH antigens. J. Biol. Chem. 300, 107577 (2024).","journal-title":"J. Biol. Chem."},{"key":"2768_CR42","doi-asserted-by":"crossref","unstructured":"Farhadi, S. A. et al. Physical tuning of galectin-3 signaling. Proc. Natl. Acad. Sci. USA. 118, e2024117118 (2021).","DOI":"10.1073\/pnas.2024117118"},{"key":"2768_CR43","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1111\/j.1749-6632.2012.06698.x","volume":"1253","author":"GR Vasta","year":"2012","unstructured":"Vasta, G. R. et al. Diversity in recognition of glycans by F-type lectins and galectins: molecular, structural, and biophysical aspects. Ann. N. Y Acad. Sci. 1253, E14\u2013E26 (2012).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"2768_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4614-0106-3_2","volume":"946","author":"GR Vasta","year":"2012","unstructured":"Vasta, G. R. Galectins as pattern recognition receptors: structure, function, and evolution. Adv. Exp. Med. Biol. 946, 21\u201336 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2768_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10038-004-0218-4","volume":"50","author":"A Iida","year":"2005","unstructured":"Iida, A., Ozaki, K., Tanaka, T. & Nakamura, Y. Fine-scale SNP map of an 11-kb genomic region at 22q13.1 containing the galectin-1 gene. J. Hum. Genet. 50, 42\u201345 (2005).","journal-title":"J. Hum. Genet."},{"key":"2768_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2023.106308","volume":"210","author":"K Pfeffer","year":"2023","unstructured":"Pfeffer, K. et al. Generation and characterization of a monoclonal antibody that binds to Galectin-1. Protein Expr. Purif. 210, 106308 (2023).","journal-title":"Protein Expr. Purif."},{"key":"2768_CR47","doi-asserted-by":"crossref","unstructured":"Cousin, J. M. & Cloninger, M. J. The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1. Int. J. Mol. Sci. 17, 1566 (2016).","DOI":"10.3390\/ijms17091566"},{"key":"2768_CR48","doi-asserted-by":"crossref","unstructured":"Yu, X. et al. Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities. Int. J. Mol. Sci. 24, 6501 (2023).","DOI":"10.3390\/ijms24076501"},{"key":"2768_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/glycob\/cwu008","volume":"24","author":"CM Guardia","year":"2014","unstructured":"Guardia, C. M. et al. Structural basis of redox-dependent modulation of galectin-1 dynamics and function. Glycobiology 24, 428\u2013441 (2014).","journal-title":"Glycobiology"},{"key":"2768_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ctrv.2013.07.007","volume":"40","author":"L Astorgues-Xerri","year":"2014","unstructured":"Astorgues-Xerri, L. et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat. Rev. 40, 307\u2013319 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"2768_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2174\/1389450054022007","volume":"6","author":"T Kadoya","year":"2005","unstructured":"Kadoya, T. & Horie, H. Structural and functional studies of galectin-1: a novel axonal regeneration-promoting activity for oxidized galectin-1. Curr. Drug Targets 6, 375\u2013383 (2005).","journal-title":"Curr. Drug Targets"},{"key":"2768_CR52","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1074\/jbc.M808925200","volume":"284","author":"SR Stowell","year":"2009","unstructured":"Stowell, S. R. et al. Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation. J. Biol. Chem. 284, 4989\u20134999 (2009).","journal-title":"J. Biol. Chem."},{"key":"2768_CR53","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1038\/sj.onc.1211029","volume":"27","author":"SH Hsieh","year":"2008","unstructured":"Hsieh, S. H. et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27, 3746\u20133753 (2008).","journal-title":"Oncogene"},{"key":"2768_CR54","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/carcin\/bgt040","volume":"34","author":"YL Hsu","year":"2013","unstructured":"Hsu, Y. L. et al. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1\/Jagged2 signaling pathway. Carcinogenesis 34, 1370\u20131381 (2013).","journal-title":"Carcinogenesis"},{"key":"2768_CR55","doi-asserted-by":"crossref","unstructured":"Negedu, M. N., Duckworth, C. A. & Yu, L. G. Galectin-2 in health and diseases. Int. J. Mol. Sci. 24, 341 (2022).","DOI":"10.3390\/ijms24010341"},{"key":"2768_CR56","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/abbs\/gmw089","volume":"48","author":"Y Si","year":"2016","unstructured":"Si, Y. et al. Human galectin-2 interacts with carbohydrates and peptides non-classically: new insight from X-ray crystallography and hemagglutination. Acta Biochim. Biophys. Sin. (Shanghai). 48, 939\u2013947 (2016).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)."},{"key":"2768_CR57","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1055\/a-1711-1055","volume":"122","author":"J Kane","year":"2022","unstructured":"Kane, J. et al. Anti-galectin-2 antibody treatment reduces atherosclerotic plaque size and alters macrophage polarity. Thromb. Haemost. 122, 1047\u20131057 (2022).","journal-title":"Thromb. Haemost."},{"key":"2768_CR58","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","volume":"17","author":"H Barrow","year":"2011","unstructured":"Barrow, H. et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin. Cancer Res. 17, 7035\u20137046 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR59","doi-asserted-by":"publisher","first-page":"9247574","DOI":"10.1155\/2017\/9247574","volume":"2017","author":"L Diaz-Alvarez","year":"2017","unstructured":"Diaz-Alvarez, L. & Ortega, E. The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. Mediators Inflamm. 2017, 9247574 (2017).","journal-title":"Mediators Inflamm."},{"key":"2768_CR60","doi-asserted-by":"publisher","first-page":"fj201701151RRR","DOI":"10.1096\/fj.201701151RRR","volume":"32","author":"A Rancourt","year":"2018","unstructured":"Rancourt, A. et al. Galectin-3 and N-acetylglucosamine promote myogenesis and improve skeletal muscle function in the mdx model of Duchenne muscular dystrophy. FASEB J. 32, fj201701151RRR (2018).","journal-title":"FASEB J."},{"key":"2768_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10863-006-9063-9","volume":"39","author":"P Nangia-Makker","year":"2007","unstructured":"Nangia-Makker, P., Nakahara, S., Hogan, V. & Raz, A. Galectin-3 in apoptosis, a novel therapeutic target. J. Bioenerg. Biomembr. 39, 79\u201384 (2007).","journal-title":"J. Bioenerg. Biomembr."},{"key":"2768_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bbamcr.2015.08.008","volume":"1863","author":"PP Ruvolo","year":"2016","unstructured":"Ruvolo, P. P. Galectin 3 as a guardian of the tumor microenvironment. Biochim. Biophys. Acta 1863, 427\u2013437 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"2768_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1177\/1535370215593826","volume":"240","author":"FL de Oliveira","year":"2015","unstructured":"de Oliveira, F. L. et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp. Biol. Med. (Maywood) 240, 1019\u20131028 (2015).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"2768_CR64","doi-asserted-by":"crossref","unstructured":"Boutin, L. et al. Galectin-3 in kidney diseases: from an old protein to a new therapeutic target. Int. J. Mol. Sci. 23, 3124 (2022).","DOI":"10.3390\/ijms23063124"},{"key":"2768_CR65","doi-asserted-by":"crossref","unstructured":"Blanda, V., Bracale, U. M., Di Taranto, M. D. & Fortunato, G. Galectin-3 in Cardiovascular Diseases. Int. J. Mol. Sci. 21, 9232 (2020).","DOI":"10.3390\/ijms21239232"},{"key":"2768_CR66","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4103\/1673-5374.391181","volume":"19","author":"BM Lozinski","year":"2024","unstructured":"Lozinski, B. M., Ta, K. & Dong, Y. Emerging role of galectin 3 in neuroinflammation and neurodegeneration. Neural Regen. Res. 19, 2004\u20132009 (2024).","journal-title":"Neural Regen. Res."},{"key":"2768_CR67","doi-asserted-by":"crossref","unstructured":"Sciacchitano, S. et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int. J. Mol. Sci. 19, 379 (2018).","DOI":"10.3390\/ijms19020379"},{"key":"2768_CR68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.acr.2022.06.001","volume":"157","author":"NBB Mohammed","year":"2023","unstructured":"Mohammed, N. B. B. et al. The pleiotropic role of galectin-3 in melanoma progression: unraveling the enigma. Adv. Cancer Res. 157, 157\u2013193 (2023).","journal-title":"Adv. Cancer Res."},{"key":"2768_CR69","doi-asserted-by":"crossref","unstructured":"Shi, Y. et al. Galectin family members: Emerging novel targets for lymphoma therapy? Front. Oncol. 12, 889034 (2022).","DOI":"10.3389\/fonc.2022.889034"},{"key":"2768_CR70","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2012-06-438234","volume":"120","author":"MC Clark","year":"2012","unstructured":"Clark, M. C. et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120, 4635\u20134644 (2012).","journal-title":"Blood"},{"key":"2768_CR71","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s13238-016-0262-9","volume":"7","author":"ZQ Cao","year":"2016","unstructured":"Cao, Z. Q. & Guo, X. L. The role of galectin-4 in physiology and diseases. Protein Cell 7, 314\u2013324 (2016).","journal-title":"Protein Cell"},{"key":"2768_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/srep33633","volume":"6","author":"JK Rustiguel","year":"2016","unstructured":"Rustiguel, J. K. et al. Full-length model of the human galectin-4 and insights into dynamics of inter-domain communication. Sci. Rep. 6, 33633 (2016).","journal-title":"Sci. Rep."},{"key":"2768_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1052959","volume":"10","author":"L Kruk","year":"2023","unstructured":"Kruk, L. et al. Galectin functions in cancer-associated inflammation and thrombosis. Front. Cardiovasc. Med. 10, 1052959 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"2768_CR74","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1074\/jbc.270.10.5032","volume":"270","author":"MA Gitt","year":"1995","unstructured":"Gitt, M. A. et al. Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes. J. Biol. Chem. 270, 5032\u20135038 (1995).","journal-title":"J. Biol. Chem."},{"key":"2768_CR75","doi-asserted-by":"crossref","unstructured":"Ruiz, F. M. et al. Structural characterization of rat galectin-5, an N-tailed monomeric proto-type-like galectin. Biomolecules 11, 1854 (2021).","DOI":"10.3390\/biom11121854"},{"key":"2768_CR76","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1074\/jbc.273.5.2961","volume":"273","author":"MA Gitt","year":"1998","unstructured":"Gitt, M. A. et al. Sequence, structure, and chromosomal mapping of the mouse Lgals6 gene, encoding galectin-6. J. Biol. Chem. 273, 2961\u20132970 (1998).","journal-title":"J. Biol. Chem."},{"key":"2768_CR77","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1074\/jbc.273.5.2954","volume":"273","author":"MA Gitt","year":"1998","unstructured":"Gitt, M. A. et al. Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract. J. Biol. Chem. 273, 2954\u20132960 (1998).","journal-title":"J. Biol. Chem."},{"key":"2768_CR78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdermsci.2016.06.008","volume":"84","author":"K Natsuga","year":"2016","unstructured":"Natsuga, K. & Watt, F. M. Galectin-6 is a novel skin anti-microbial peptide that is modulated by the skin barrier and microbiome. J. Dermatol. Sci. 84, 97\u201399 (2016).","journal-title":"J. Dermatol. Sci."},{"key":"2768_CR79","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41418-022-01108-7","volume":"30","author":"NA Pinto","year":"2023","unstructured":"Pinto, N. A. et al. Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programs. Cell Death Differ. 30, 906\u2013921 (2023).","journal-title":"Cell Death Differ."},{"key":"2768_CR80","doi-asserted-by":"crossref","unstructured":"Chen, H. L. et al. Galectin-7 regulates keratinocyte proliferation and differentiation through JNK-miR-203-p63 signaling. J. Invest. Dermatol. 136, 182\u2013191 (2016).","DOI":"10.1038\/JID.2015.366"},{"key":"2768_CR81","doi-asserted-by":"crossref","unstructured":"Advedissian, T., Deshayes, F. & Viguier, M. Galectin-7 in epithelial homeostasis and carcinomas. Int. J. Mol. Sci. 18, 2760 (2017).","DOI":"10.3390\/ijms18122760"},{"key":"2768_CR82","doi-asserted-by":"crossref","unstructured":"Sewgobind, N. V., Albers, S. & Pieters, R. J. Functions and inhibition of galectin-7, an emerging target in cellular pathophysiology. Biomolecules 11, 1720 (2021).","DOI":"10.3390\/biom11111720"},{"key":"2768_CR83","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2353\/ajpath.2010.090876","volume":"176","author":"M Demers","year":"2010","unstructured":"Demers, M. et al. Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am. J. Pathol. 176, 3023\u20133031 (2010).","journal-title":"Am. J. Pathol."},{"key":"2768_CR84","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41388-022-02525-1","volume":"41","author":"J An","year":"2022","unstructured":"An, J. et al. Identification of galectin-7 as a crucial metastatic enhancer of squamous cell carcinoma associated with immunosuppression. Oncogene 41, 5319\u20135330 (2022).","journal-title":"Oncogene"},{"key":"2768_CR85","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7314\/APJCP.2016.17.2.455","volume":"17","author":"M Kaur","year":"2016","unstructured":"Kaur, M., Kaur, T., Kamboj, S. S. & Singh, J. Roles of galectin-7 in cancer. Asian Pac. J. Cancer Prev. 17, 455\u2013461 (2016).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2768_CR86","doi-asserted-by":"publisher","first-page":"31285","DOI":"10.1074\/jbc.M100340200","volume":"276","author":"Y Levy","year":"2001","unstructured":"Levy, Y. et al. Galectin-8 functions as a matricellular modulator of cell adhesion. J. Biol. Chem. 276, 31285\u201331295 (2001).","journal-title":"J. Biol. Chem."},{"key":"2768_CR87","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/med.22041","volume":"44","author":"E Puric","year":"2024","unstructured":"Puric, E., Nilsson, U. J. & Anderluh, M. Galectin-8 inhibition and functions in immune response and tumor biology. Med. Res. Rev. 44, 2236\u20132265 (2024).","journal-title":"Med. Res. Rev."},{"key":"2768_CR88","doi-asserted-by":"publisher","first-page":"20547","DOI":"10.1074\/jbc.M802495200","volume":"283","author":"SR Stowell","year":"2008","unstructured":"Stowell, S. R. et al. Dimeric galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain. J. Biol. Chem. 283, 20547\u201320559 (2008).","journal-title":"J. Biol. Chem."},{"key":"2768_CR89","doi-asserted-by":"crossref","unstructured":"Zick, Y. Galectin-8, cytokines, and the storm. Biochem Soc. Trans. 50, 135\u2013149 (2022).","DOI":"10.1042\/BST20200677"},{"key":"2768_CR90","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell Rep. Med 5, 101374 (2024).","DOI":"10.1016\/j.xcrm.2023.101374"},{"key":"2768_CR91","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv, Y. et al. A new emerging target in cancer immunotherapy: galectin-9 (LGALS9). Genes Dis. 10, 2366\u20132382 (2023).","journal-title":"Genes Dis."},{"key":"2768_CR92","doi-asserted-by":"publisher","first-page":"104287","DOI":"10.1016\/j.cellimm.2021.104287","volume":"361","author":"P Moar","year":"2021","unstructured":"Moar, P. & Tandon, R. Galectin-9 as a biomarker of disease severity. Cell Immunol. 361, 104287 (2021).","journal-title":"Cell Immunol."},{"key":"2768_CR93","doi-asserted-by":"publisher","first-page":"994830","DOI":"10.3389\/fimmu.2022.994830","volume":"13","author":"A Shete","year":"2022","unstructured":"Shete, A., Bhat, M., Sawant, J. & Deshpande, S. Both N- and C-terminal domains of galectin-9 are capable of inducing HIV reactivation despite mediating differential immunomodulatory functionalities. Front. Immunol. 13, 994830 (2022).","journal-title":"Front. Immunol."},{"key":"2768_CR94","doi-asserted-by":"publisher","first-page":"35884","DOI":"10.1074\/jbc.M606648200","volume":"281","author":"M Nagae","year":"2006","unstructured":"Nagae, M. et al. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 281, 35884\u201335893 (2006).","journal-title":"J. Biol. Chem."},{"key":"2768_CR95","doi-asserted-by":"crossref","unstructured":"Fujita, K. et al. Cancer therapy due to apoptosis: galectin-9. Int. J. Mol. Sci. 18, 74 (2017).","DOI":"10.3390\/ijms18010074"},{"key":"2768_CR96","doi-asserted-by":"crossref","unstructured":"Iwasaki-Hozumi, H., Chagan-Yasutan, H., Ashino, Y. & Hattori, T. Blood levels of galectin-9, an immuno-regulating molecule, reflect the severity for the acute and chronic infectious diseases. Biomolecules 11, 430 (2021).","DOI":"10.3390\/biom11030430"},{"key":"2768_CR97","doi-asserted-by":"crossref","unstructured":"Morishita, A. et al. Galectin-9 in gastroenterological cancer. Int. J. Mol. Sci. 24, 6174 (2023).","DOI":"10.3390\/ijms24076174"},{"key":"2768_CR98","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige, Y. et al. A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17, 341\u2013352 (2015).","journal-title":"Cell Stem Cell"},{"key":"2768_CR99","doi-asserted-by":"publisher","first-page":"1469794","DOI":"10.3389\/fimmu.2024.1469794","volume":"15","author":"RK Shil","year":"2024","unstructured":"Shil, R. K., Mohammed, N. B. B. & Dimitroff, C. J. Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma. Front. Immunol. 15, 1469794 (2024).","journal-title":"Front. Immunol."},{"key":"2768_CR100","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood-2007-01-069229","volume":"110","author":"J Kubach","year":"2007","unstructured":"Kubach, J. et al. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110, 1550\u20131558 (2007).","journal-title":"Blood"},{"key":"2768_CR101","first-page":"85","volume":"29","author":"J Su","year":"2019","unstructured":"Su, J. et al. Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 29, 85\u201393 (2019).","journal-title":"Glycobiology"},{"key":"2768_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/glycob\/cwx107","volume":"28","author":"J Su","year":"2018","unstructured":"Su, J. et al. Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 28, 159\u2013168 (2018).","journal-title":"Glycobiology"},{"key":"2768_CR103","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3389\/fchem.2019.00823","volume":"7","author":"CP Modenutti","year":"2019","unstructured":"Modenutti, C. P., Capurro, J. I. B., Di Lella, S. & Marti, M. A. The structural biology of galectin-ligand recognition: current advances in modeling tools, protein engineering, and inhibitor design. Front. Chem. 7, 823 (2019).","journal-title":"Front. Chem."},{"key":"2768_CR104","doi-asserted-by":"crossref","unstructured":"Tomizawa, H. et al. Galectin-10 as a potential biomarker for eosinophilic diseases. Biomolecules 12, 1385 (2022).","DOI":"10.3390\/biom12101385"},{"key":"2768_CR105","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/JLB.3AB0220-311R","volume":"108","author":"RCN Melo","year":"2020","unstructured":"Melo, R. C. N. et al. Galectin-10, the protein that forms Charcot\u2013Leyden crystals, is not stored in granules but resides in the peripheral cytoplasm of human eosinophils. J. Leukoc. Biol. 108, 139\u2013149 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"2768_CR106","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaci.2020.01.013","volume":"146","author":"MM Grozdanovic","year":"2020","unstructured":"Grozdanovic, M. M. et al. Charcot\u2013Leyden crystal protein\/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis. J. Allergy Clin. Immunol. 146, 377\u2013389 e310 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2768_CR107","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s42003-020-01179-7","volume":"3","author":"D Sakthivel","year":"2020","unstructured":"Sakthivel, D. et al. The oligomeric assembly of galectin-11 is critical for anti-parasitic activity in sheep (Ovis aries). Commun. Biol. 3, 464 (2020).","journal-title":"Commun. Biol."},{"key":"2768_CR108","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1095\/biolreprod.107.063594","volume":"77","author":"SK Lewis","year":"2007","unstructured":"Lewis, S. K. et al. Galectin 15 (LGALS15): a gene uniquely expressed in the uteri of sheep and goats that functions in trophoblast attachment. Biol. Reprod. 77, 1027\u20131036 (2007).","journal-title":"Biol. Reprod."},{"key":"2768_CR109","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4510","volume":"6","author":"D Sakthivel","year":"2018","unstructured":"Sakthivel, D. et al. Proteomic identification of galectin-11 and 14 ligands from Haemonchus contortus. PeerJ 6, e4510 (2018).","journal-title":"PeerJ"},{"key":"2768_CR110","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ijpara.2015.06.003","volume":"45","author":"SJ Preston","year":"2015","unstructured":"Preston, S. J. et al. Galectin-11: a novel host mediator targeting specific stages of the gastrointestinal nematode parasite, Haemonchus contortus. Int. J. Parasitol. 45, 791\u2013796 (2015).","journal-title":"Int. J. Parasitol."},{"key":"2768_CR111","doi-asserted-by":"publisher","first-page":"9731","DOI":"10.1073\/pnas.0903568106","volume":"106","author":"NG Than","year":"2009","unstructured":"Than, N. G. et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc. Natl. Acad. Sci. USA 106, 9731\u20139736 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2768_CR112","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1096\/fj.07-9308com","volume":"22","author":"JL Farmer","year":"2008","unstructured":"Farmer, J. L. et al. Galectin 15 (LGALS15) functions in trophectoderm migration and attachment. FASEB J. 22, 548\u2013560 (2008).","journal-title":"FASEB J."},{"key":"2768_CR113","doi-asserted-by":"publisher","first-page":"7982","DOI":"10.1073\/pnas.0402669101","volume":"101","author":"CA Gray","year":"2004","unstructured":"Gray, C. A. et al. Discovery and characterization of an epithelial-specific galectin in the endometrium that forms crystals in the trophectoderm. Proc. Natl. Acad. Sci. USA 101, 7982\u20137987 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2768_CR114","doi-asserted-by":"publisher","first-page":"34089","DOI":"10.1074\/jbc.M105097200","volume":"276","author":"K Hotta","year":"2001","unstructured":"Hotta, K. et al. Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity. J. Biol. Chem. 276, 34089\u201334097 (2001).","journal-title":"J. Biol. Chem."},{"key":"2768_CR115","doi-asserted-by":"crossref","unstructured":"Tsao, C. H. et al. Galectin-12 in the regulation of sebocyte proliferation, lipid metabolism, and immune responses. Biomolecules 15, 837 (2025).","DOI":"10.3390\/biom15060837"},{"key":"2768_CR116","doi-asserted-by":"publisher","first-page":"20252","DOI":"10.1074\/jbc.M010914200","volume":"276","author":"RY Yang","year":"2001","unstructured":"Yang, R. Y. et al. Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J. Biol. Chem. 276, 20252\u201320260 (2001).","journal-title":"J. Biol. Chem."},{"key":"2768_CR117","doi-asserted-by":"crossref","unstructured":"Wan, L., Yang, R. Y. & Liu, F. T. Galectin-12 in cellular differentiation, apoptosis and polarization. Int. J. Mol. Sci. 19, 176 (2018).","DOI":"10.3390\/ijms19010176"},{"key":"2768_CR118","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yexcr.2019.03.032","volume":"379","author":"EM Katzenmaier","year":"2019","unstructured":"Katzenmaier, E. M. et al. Deciphering the galectin-12 protein interactome reveals a major impact of galectin-12 on glutamine anaplerosis in colon cancer cells. Exp. Cell Res. 379, 129\u2013139 (2019).","journal-title":"Exp. Cell Res."},{"key":"2768_CR119","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3389\/fimmu.2019.01240","volume":"10","author":"A Balogh","year":"2019","unstructured":"Balogh, A. et al. Placental galectins are key players in regulating the maternal adaptive immune response. Front. Immunol. 10, 1240 (2019).","journal-title":"Front. Immunol."},{"key":"2768_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088024","volume":"13","author":"O Oravecz","year":"2022","unstructured":"Oravecz, O. et al. Placental galectins regulate innate and adaptive immune responses in pregnancy. Front. Immunol. 13, 1088024 (2022).","journal-title":"Front. Immunol."},{"key":"2768_CR121","doi-asserted-by":"crossref","unstructured":"Sammar, M. et al. Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy. Int. J. Mol. Sci. 20, 3192 (2019).","DOI":"10.3390\/ijms20133192"},{"key":"2768_CR122","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/glycob\/cwz081","volume":"30","author":"T Yang","year":"2020","unstructured":"Yang, T. et al. Galectin-13\/placental protein 13: redox-active disulfides as switches for regulating structure, function and cellular distribution. Glycobiology 30, 120\u2013129 (2020).","journal-title":"Glycobiology"},{"key":"2768_CR123","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/febs.15441","volume":"288","author":"Y Si","year":"2021","unstructured":"Si, Y. et al. Structure-function studies of galectin-14, an important effector molecule in embryology. FEBS J. 288, 1041\u20131055 (2021).","journal-title":"FEBS J."},{"key":"2768_CR124","doi-asserted-by":"publisher","first-page":"14916","DOI":"10.1074\/jbc.M200214200","volume":"277","author":"JL Dunphy","year":"2002","unstructured":"Dunphy, J. L. et al. Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J. Biol. Chem. 277, 14916\u201314924 (2002).","journal-title":"J. Biol. Chem."},{"key":"2768_CR125","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.placenta.2014.11.019","volume":"36","author":"L Unverdorben","year":"2015","unstructured":"Unverdorben, L. et al. Galectin-13\/PP-13 expression in term placentas of gestational diabetes mellitus pregnancies. Placenta 36, 191\u2013198 (2015).","journal-title":"Placenta"},{"key":"2768_CR126","doi-asserted-by":"crossref","unstructured":"Zhang, H. L. et al. Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis propagation. Nat. Chem. Biol. 21, 1531\u20131543 (2025).","DOI":"10.1038\/s41589-025-01888-2"},{"key":"2768_CR127","doi-asserted-by":"crossref","unstructured":"Kaminker, J. D. & Timoshenko, A. V. Expression, regulation, and functions of the galectin-16 gene in human cells and tissues. Biomolecules 11, 1909 (2021).","DOI":"10.3390\/biom11121909"},{"key":"2768_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129755","volume":"1865","author":"Y Si","year":"2021","unstructured":"Si, Y. et al. Human galectin-16 has a pseudo ligand binding site and plays a role in regulating c-Rel-mediated lymphocyte activity. Biochim Biophys. Acta Gen. Subj. 1865, 129755 (2021).","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"key":"2768_CR129","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semcdb.2018.02.022","volume":"83","author":"SJ Popa","year":"2018","unstructured":"Popa, S. J., Stewart, S. E. & Moreau, K. Unconventional secretion of annexins and galectins. Semin Cell Dev. Biol. 83, 42\u201350 (2018).","journal-title":"Semin Cell Dev. Biol."},{"key":"2768_CR130","doi-asserted-by":"publisher","first-page":"R406","DOI":"10.1016\/j.cub.2022.03.065","volume":"32","author":"S Banfer","year":"2022","unstructured":"Banfer, S. & Jacob, R. Galectins. Curr. Biol. 32, R406\u2013R408 (2022).","journal-title":"Curr. Biol."},{"key":"2768_CR131","doi-asserted-by":"publisher","first-page":"129449","DOI":"10.1016\/j.bbagen.2019.129449","volume":"1864","author":"TJ Kutzner","year":"2020","unstructured":"Kutzner, T. J. et al. How presence of a signal peptide affects human galectins-1 and -4: clues to explain common absence of a leader sequence among adhesion\/growth-regulatory galectins. Biochim. Biophys. Acta Gen. Subj. 1864, 129449 (2020).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2768_CR132","doi-asserted-by":"publisher","first-page":"100045","DOI":"10.1016\/j.tcsw.2020.100045","volume":"6","author":"MJ Cohen","year":"2020","unstructured":"Cohen, M. J., Chirico, W. J. & Lipke, P. N. Through the back door: unconventional protein secretion. Cell Surf. 6, 100045 (2020).","journal-title":"Cell Surf."},{"key":"2768_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00466-9","volume":"11","author":"D Liu","year":"2023","unstructured":"Liu, D., Zhu, H. & Li, C. Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy. Biomark. Res 11, 22 (2023).","journal-title":"Biomark. Res"},{"key":"2768_CR134","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1242\/jcs.103630","volume":"125","author":"C Rabouille","year":"2012","unstructured":"Rabouille, C., Malhotra, V. & Nickel, W. Diversity in unconventional protein secretion. J. Cell Sci. 125, 5251\u20135255 (2012).","journal-title":"J. Cell Sci."},{"key":"2768_CR135","doi-asserted-by":"crossref","unstructured":"Banfer, S. & Jacob, R. Galectins in intra- and extracellular vesicles. Biomolecules 10, 430 (2020).","DOI":"10.3390\/biom10091232"},{"key":"2768_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-2055-7_1","volume":"2442","author":"H Verkerke","year":"2022","unstructured":"Verkerke, H. et al. Galectins: an ancient family of carbohydrate binding proteins with modern functions. Methods Mol. Biol. 2442, 1\u201340 (2022).","journal-title":"Methods Mol. Biol."},{"key":"2768_CR137","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/978-1-4939-1396-1_28","volume":"1207","author":"RJ Patterson","year":"2015","unstructured":"Patterson, R. J., Haudek, K. C., Voss, P. G. & Wang, J. L. Examination of the role of galectins in pre-mRNA splicing. Methods Mol. Biol. 1207, 431\u2013449 (2015).","journal-title":"Methods Mol. Biol."},{"key":"2768_CR138","doi-asserted-by":"crossref","unstructured":"Chou, F. C., Chen, H. Y., Kuo, C. C. & Sytwu, H. K. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 19, 430 (2018).","DOI":"10.3390\/ijms19020430"},{"key":"2768_CR139","doi-asserted-by":"crossref","unstructured":"Girotti, M. R., Salatino, M., Dalotto-Moreno, T. & Rabinovich, G. A. Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression. J. Exp. Med. 217, e20182041(2020).","DOI":"10.1084\/jem.20182041"},{"key":"2768_CR140","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12, 636568 (2021).","journal-title":"Front. Immunol."},{"key":"2768_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106700","volume":"86","author":"S Tang","year":"2020","unstructured":"Tang, S. et al. Mechanisms of immune escape in the cancer immune cycle. Int. Immunopharmacol. 86, 106700 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2768_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1948","volume":"3","author":"S Feau","year":"2012","unstructured":"Feau, S. et al. The CD4(+) T-cell help signal is transmitted from APC to CD8(+) T-cells via CD27-CD70 interactions. Nat. Commun. 3, 948 (2012).","journal-title":"Nat. Commun."},{"key":"2768_CR143","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.coi.2023.102345","volume":"83","author":"E Bawden","year":"2023","unstructured":"Bawden, E. & Gebhardt, T. The multifaceted roles of CD4(+) T cells and MHC class II in cancer surveillance. Curr. Opin. Immunol. 83, 102345 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"2768_CR144","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","volume":"15","author":"I Voskoboinik","year":"2015","unstructured":"Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388\u2013400 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2768_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando, M. et al. Memory T cell, exhaustion, and tumor immunity. Immunol. Med. 43, 1\u20139 (2020).","journal-title":"Immunol. Med."},{"key":"2768_CR146","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23, 90\u2013105 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2768_CR147","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li, Z., Li, D., Tsun, A. & Li, B. FOXP3+ regulatory T cells and their functional regulation. Cell Mol. Immunol. 12, 558\u2013565 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"2768_CR148","doi-asserted-by":"publisher","first-page":"1328193","DOI":"10.3389\/fimmu.2024.1328193","volume":"15","author":"O Goldmann","year":"2024","unstructured":"Goldmann, O., Nwofor, O. V., Chen, Q. & Medina, E. Mechanisms underlying immunosuppression by regulatory cells. Front Immunol. 15, 1328193 (2024).","journal-title":"Front Immunol."},{"key":"2768_CR149","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12170","volume":"259","author":"KS Smigiel","year":"2014","unstructured":"Smigiel, K. S., Srivastava, S., Stolley, J. M. & Campbell, D. J. Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol. Rev. 259, 40\u201359 (2014).","journal-title":"Immunol. Rev."},{"key":"2768_CR150","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118 (2017).","journal-title":"Cell Res."},{"key":"2768_CR151","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/IGC.0000000000000578","volume":"26","author":"WC Chang","year":"2016","unstructured":"Chang, W. C. et al. Regulatory T cells suppress natural killer cell immunity in patients with human cervical carcinoma. Int. J. Gynecol. Cancer 26, 156\u2013162 (2016).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2768_CR152","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1016\/j.jmb.2016.03.021","volume":"428","author":"GA Rabinovich","year":"2016","unstructured":"Rabinovich, G. A. & Conejo-Garcia, J. R. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 428, 3266\u20133281 (2016).","journal-title":"J. Mol. Biol."},{"key":"2768_CR153","doi-asserted-by":"crossref","unstructured":"Torres, N. I. et al. Do galectins serve as soluble ligands for immune checkpoint receptors? J. Immunother. Cancer 12, e008984 (2024).","DOI":"10.1136\/jitc-2024-008984"},{"key":"2768_CR154","doi-asserted-by":"crossref","unstructured":"Huang, Y. et al. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules 11, 1398 (2021).","DOI":"10.3390\/biom11101398"},{"key":"2768_CR155","doi-asserted-by":"publisher","first-page":"E3769","DOI":"10.1073\/pnas.1722434115","volume":"115","author":"CA Orozco","year":"2018","unstructured":"Orozco, C. A. et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc. Natl. Acad. Sci. USA 115, E3769\u2013E3778 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2768_CR156","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1074\/jbc.M109.066191","volume":"285","author":"LA Earl","year":"2010","unstructured":"Earl, L. A., Bi, S. & Baum, L. G. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J. Biol. Chem. 285, 2232\u20132244 (2010).","journal-title":"J. Biol. Chem."},{"key":"2768_CR157","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2014.01.059","volume":"156","author":"P Stanley","year":"2014","unstructured":"Stanley, P. Galectin-1 Pulls the strings on VEGFR2. Cell 156, 625\u2013626 (2014).","journal-title":"Cell"},{"key":"2768_CR158","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1172\/JCI129025","volume":"129","author":"DK Nambiar","year":"2019","unstructured":"Nambiar, D. K. et al. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J. Clin. Invest. 129, 5553\u20135567 (2019).","journal-title":"J. Clin. Invest."},{"key":"2768_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106984","volume":"26","author":"AM Rudjord-Levann","year":"2023","unstructured":"Rudjord-Levann, A. M. et al. Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1. iScience 26, 106984 (2023).","journal-title":"iScience"},{"key":"2768_CR160","doi-asserted-by":"publisher","first-page":"1250559","DOI":"10.3389\/fimmu.2023.1250559","volume":"14","author":"J Mabbitt","year":"2023","unstructured":"Mabbitt, J. et al. Resistance to anti-PD-1\/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1\/PD-L1. Front. Immunol. 14, 1250559 (2023).","journal-title":"Front. Immunol."},{"key":"2768_CR161","doi-asserted-by":"crossref","unstructured":"Greisen, S. R. et al. Gal-3 blocks the binding between PD-1 and pembrolizumab. J. Immunother. Cancer 12, e009952 (2024).","DOI":"10.1136\/jitc-2024-009952"},{"key":"2768_CR162","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","volume":"36","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia 36, 138\u2013154 (2022).","journal-title":"Leukemia"},{"key":"2768_CR163","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","volume":"510","author":"S Kandel","year":"2021","unstructured":"Kandel, S., Adhikary, P., Li, G. & Cheng, K. The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett. 510, 67\u201378 (2021).","journal-title":"Cancer Lett."},{"key":"2768_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12, 832 (2021).","journal-title":"Nat. Commun."},{"key":"2768_CR165","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2326-6066.CIR-23-0496","volume":"12","author":"R Huang","year":"2024","unstructured":"Huang, R. et al. LILRB3 supports immunosuppressive activity of myeloid cells and tumor development. Cancer Immunol. Res. 12, 350\u2013362 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2768_CR166","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/CIRCULATIONAHA.105.535294","volume":"112","author":"R Khurana","year":"2005","unstructured":"Khurana, R., Simons, M., Martin, J. F. & Zachary, I. C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112, 1813\u20131824 (2005).","journal-title":"Circulation"},{"key":"2768_CR167","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","volume":"156","author":"DO Croci","year":"2014","unstructured":"Croci, D. O. et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744\u2013758 (2014).","journal-title":"Cell"},{"key":"2768_CR168","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10456-014-9431-8","volume":"17","author":"MH Wu","year":"2014","unstructured":"Wu, M. H. et al. Galectin-1 induces vascular permeability through the neuropilin-1\/vascular endothelial growth factor receptor-1 complex. Angiogenesis 17, 839\u2013849 (2014).","journal-title":"Angiogenesis"},{"key":"2768_CR169","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/glycob\/cwu083","volume":"24","author":"DO Croci","year":"2014","unstructured":"Croci, D. O. et al. Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment. Glycobiology 24, 1283\u20131290 (2014).","journal-title":"Glycobiology"},{"key":"2768_CR170","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1084\/jem.20111665","volume":"209","author":"DO Croci","year":"2012","unstructured":"Croci, D. O. et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi\u2019s sarcoma. J. Exp. Med. 209, 1985\u20132000 (2012).","journal-title":"J. Exp. Med."},{"key":"2768_CR171","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1084\/jem.20090121","volume":"207","author":"AI Markowska","year":"2010","unstructured":"Markowska, A. I., Liu, F. T. & Panjwani, N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 207, 1981\u20131993 (2010).","journal-title":"J. Exp. Med."},{"key":"2768_CR172","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00281-024-01014-9","volume":"46","author":"V Thijssen","year":"2024","unstructured":"Thijssen, V. Vascular galectins in tumor angiogenesis and cancer immunity. Semin Immunopathol. 46, 3 (2024).","journal-title":"Semin Immunopathol."},{"key":"2768_CR173","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/ijc.25254","volume":"127","author":"P Nangia-Makker","year":"2010","unstructured":"Nangia-Makker, P. et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J. Cancer 127, 2530\u20132541 (2010).","journal-title":"Int J. Cancer"},{"key":"2768_CR174","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1096\/fj.09-144907","volume":"25","author":"VM Delgado","year":"2011","unstructured":"Delgado, V. M. et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the \u201ctandem-repeat\u201d lectin galectin-8. FASEB J. 25, 242\u2013254 (2011).","journal-title":"FASEB J."},{"key":"2768_CR175","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/carcin\/bgz002","volume":"40","author":"P Zamorano","year":"2019","unstructured":"Zamorano, P. et al. Galectin-8 induces endothelial hyperpermeability through the eNOS pathway involving S-nitrosylation-mediated adherens junction disassembly. Carcinogenesis 40, 313\u2013323 (2019).","journal-title":"Carcinogenesis"},{"key":"2768_CR176","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/bjc.2013.793","volume":"110","author":"C Chen","year":"2014","unstructured":"Chen, C. et al. Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis. Br. J. Cancer 110, 741\u2013752 (2014).","journal-title":"Br. J. Cancer"},{"key":"2768_CR177","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10456-018-9607-8","volume":"21","author":"E Aanhane","year":"2018","unstructured":"Aanhane, E. et al. Different angioregulatory activity of monovalent galectin-9 isoforms. Angiogenesis 21, 545\u2013555 (2018).","journal-title":"Angiogenesis"},{"key":"2768_CR178","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1096\/fj.201901817R","volume":"34","author":"SM Maller","year":"2020","unstructured":"Maller, S. M. et al. An adipose tissue galectin controls endothelial cell function via preferential recognition of 3-fucosylated glycans. FASEB J. 34, 735\u2013753 (2020).","journal-title":"FASEB J."},{"key":"2768_CR179","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/cas.12539","volume":"105","author":"XJ He","year":"2014","unstructured":"He, X. J. et al. Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin beta1. Cancer Sci. 105, 1402\u20131410 (2014).","journal-title":"Cancer Sci."},{"key":"2768_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-024-00490-5","volume":"57","author":"E Perez-Moreno","year":"2024","unstructured":"Perez-Moreno, E. et al. Galectins in epithelial-mesenchymal transition: roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis. Biol. Res. 57, 14 (2024).","journal-title":"Biol. Res."},{"key":"2768_CR181","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1242\/jcs.045674","volume":"122","author":"C Saravanan","year":"2009","unstructured":"Saravanan, C., Liu, F. T., Gipson, I. K. & Panjwani, N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J. Cell Sci. 122, 3684\u20133693 (2009).","journal-title":"J. Cell Sci."},{"key":"2768_CR182","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/19336918.2020.1764170","volume":"14","author":"M Gonzalez-Andrades","year":"2020","unstructured":"Gonzalez-Andrades, M. et al. Golgi alpha1,2-mannosidase I induces clustering and compartmentalization of CD147 during epithelial cell migration. Cell Adh Migr. 14, 96\u2013105 (2020).","journal-title":"Cell Adh Migr."},{"key":"2768_CR183","first-page":"3141","volume":"127","author":"J Mauris","year":"2014","unstructured":"Mauris, J. et al. Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3. J. Cell Sci. 127, 3141\u20133148 (2014).","journal-title":"J. Cell Sci."},{"key":"2768_CR184","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1091\/mbc.E16-05-0301","volume":"29","author":"C Oyanadel","year":"2018","unstructured":"Oyanadel, C. et al. Galectin-8 induces partial epithelial-mesenchymal transition with invasive tumorigenic capabilities involving a FAK\/EGFR\/proteasome pathway in Madin-Darby canine kidney cells. Mol. Biol. Cell 29, 557\u2013574 (2018).","journal-title":"Mol. Biol. Cell"},{"key":"2768_CR185","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1164\/rccm.200608-1243OC","volume":"176","author":"S Katoh","year":"2007","unstructured":"Katoh, S. et al. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med. 176, 27\u201335 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2768_CR186","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/glycob\/cwn062","volume":"18","author":"A Nobumoto","year":"2008","unstructured":"Nobumoto, A. et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18, 735\u2013744 (2008).","journal-title":"Glycobiology"},{"key":"2768_CR187","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/neuonc\/noz093","volume":"21","author":"TC Shih","year":"2019","unstructured":"Shih, T. C. et al. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors. Neuro Oncol. 21, 1389\u20131400 (2019).","journal-title":"Neuro Oncol."},{"key":"2768_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.526","volume":"5","author":"P Zhang","year":"2014","unstructured":"Zhang, P. et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 5, e991 (2014).","journal-title":"Cell Death Dis."},{"key":"2768_CR189","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/378736a0","volume":"378","author":"NL Perillo","year":"1995","unstructured":"Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736\u2013739 (1995).","journal-title":"Nature"},{"key":"2768_CR190","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.4049\/jimmunol.163.7.3801","volume":"163","author":"KE Pace","year":"1999","unstructured":"Pace, K. E., Lee, C., Stewart, P. L. & Baum, L. G. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 163, 3801\u20133811 (1999).","journal-title":"J. Immunol."},{"key":"2768_CR191","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.4049\/jimmunol.167.10.5697","volume":"167","author":"JT Nguyen","year":"2001","unstructured":"Nguyen, J. T. et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J. Immunol. 167, 5697\u20135707 (2001).","journal-title":"J. Immunol."},{"key":"2768_CR192","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1074\/jbc.M209595200","volume":"278","author":"M Amano","year":"2003","unstructured":"Amano, M., Galvan, M., He, J. & Baum, L. G. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J. Biol. Chem. 278, 7469\u20137475 (2003).","journal-title":"J. Biol. Chem."},{"key":"2768_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.1","volume":"1","author":"B Brandt","year":"2010","unstructured":"Brandt, B., Abou-Eladab, E. F., Tiedge, M. & Walzel, H. Role of the JNK\/c-Jun\/AP-1 signaling pathway in galectin-1-induced T-cell death. Cell Death Dis. 1, e23 (2010).","journal-title":"Cell Death Dis."},{"key":"2768_CR194","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1073\/pnas.93.13.6737","volume":"93","author":"RY Yang","year":"1996","unstructured":"Yang, R. Y., Hsu, D. K. & Liu, F. T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl. Acad. Sci. USA 93, 6737\u20136742 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2768_CR195","first-page":"5272","volume":"57","author":"S Akahani","year":"1997","unstructured":"Akahani, S. et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57, 5272\u20135276 (1997).","journal-title":"Cancer Res."},{"key":"2768_CR196","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1158\/0008-5472.CAN-05-3750","volume":"66","author":"T Fukumori","year":"2006","unstructured":"Fukumori, T. et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 66, 3114\u20133119 (2006).","journal-title":"Cancer Res."},{"key":"2768_CR197","doi-asserted-by":"publisher","first-page":"15819","DOI":"10.1074\/jbc.M200154200","volume":"277","author":"F Yu","year":"2002","unstructured":"Yu, F., Finley, R. L. Jr., Raz, A. & Kim, H. R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 277, 15819\u201315827 (2002).","journal-title":"J. Biol. Chem."},{"key":"2768_CR198","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","volume":"313","author":"AU Newlaczyl","year":"2011","unstructured":"Newlaczyl, A. U. & Yu, L. G. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 313, 123\u2013128 (2011).","journal-title":"Cancer Lett."},{"key":"2768_CR199","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4049\/jimmunol.176.2.778","volume":"176","author":"BN Stillman","year":"2006","unstructured":"Stillman, B. N. et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176, 778\u2013789 (2006).","journal-title":"J. Immunol."},{"key":"2768_CR200","doi-asserted-by":"crossref","unstructured":"Lidstrom, T. et al. Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer. Cancer Immunol. Res. 11, 72\u201392 (2023).","DOI":"10.1158\/2326-6066.CIR-21-1088"},{"key":"2768_CR201","doi-asserted-by":"crossref","unstructured":"Satelli, A., Rao, P. S., Thirumala, S. & Rao, U. S. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J. Cancer 129, 799\u2013809 (2011).","DOI":"10.1002\/ijc.25750"},{"key":"2768_CR202","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1074\/jbc.M109360200","volume":"277","author":"I Kuwabara","year":"2002","unstructured":"Kuwabara, I. et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J. Biol. Chem. 277, 3487\u20133497 (2002).","journal-title":"J. Biol. Chem."},{"key":"2768_CR203","doi-asserted-by":"publisher","first-page":"12670","DOI":"10.1074\/jbc.M808949200","volume":"284","author":"A Norambuena","year":"2009","unstructured":"Norambuena, A. et al. Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1\/2 activation supported by protein kinase A down-regulation. J. Biol. Chem. 284, 12670\u201312679 (2009).","journal-title":"J. Biol. Chem."},{"key":"2768_CR204","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245\u20131252 (2005).","journal-title":"Nat. Immunol."},{"key":"2768_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110336","volume":"120","author":"L Zheng","year":"2023","unstructured":"Zheng, L. et al. The interrelation of galectins and autophagy. Int. Immunopharmacol. 120, 110336 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2768_CR206","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.devcel.2019.10.025","volume":"52","author":"J Jia","year":"2020","unstructured":"Jia, J. et al. Galectin-3 coordinates a cellular system for lysosomal repair and removal. Dev. Cell 52, 69\u201387.e68 (2020).","journal-title":"Dev. Cell"},{"key":"2768_CR207","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nature10744","volume":"482","author":"TL Thurston","year":"2012","unstructured":"Thurston, T. L. et al. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414\u2013418 (2012).","journal-title":"Nature"},{"key":"2768_CR208","first-page":"27","volume":"41","author":"DH Kwon","year":"2018","unstructured":"Kwon, D. H. & Song, H. K. A structural view of xenophagy, a battle between host and microbes. Mol. Cells 41, 27\u201334 (2018).","journal-title":"Mol. Cells"},{"key":"2768_CR209","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molcel.2018.03.009","volume":"70","author":"J Jia","year":"2018","unstructured":"Jia, J. et al. Galectins control mTOR in response to endomembrane damage. Mol. Cell 70, 120\u2013135.e128 (2018).","journal-title":"Mol. Cell"},{"key":"2768_CR210","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/15548627.2018.1505155","volume":"15","author":"J Jia","year":"2019","unstructured":"Jia, J. et al. Galectins control MTOR and AMPK in response to lysosomal damage to induce autophagy. Autophagy 15, 169\u2013171 (2019).","journal-title":"Autophagy"},{"key":"2768_CR211","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molcel.2019.12.028","volume":"77","author":"J Jia","year":"2020","unstructured":"Jia, J. et al. AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system. Mol. Cell 77, 951\u2013969.e959 (2020).","journal-title":"Mol. Cell"},{"key":"2768_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35334-x","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Intracellular galectin-3 is a lipopolysaccharide sensor that promotes glycolysis through mTORC1 activation. Nat. Commun. 13, 7578 (2022).","journal-title":"Nat. Commun."},{"key":"2768_CR213","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yexcr.2014.06.001","volume":"326","author":"MJ Lim","year":"2014","unstructured":"Lim, M. J. et al. Induction of galectin-1 by TGF-beta1 accelerates fibrosis through enhancing nuclear retention of Smad2. Exp. Cell Res. 326, 125\u2013135 (2014).","journal-title":"Exp. Cell Res."},{"key":"2768_CR214","doi-asserted-by":"crossref","unstructured":"Bogut, A. et al. Galectin-1 in pancreatic ductal adenocarcinoma: bridging tumor biology, immune evasion, and therapeutic opportunities. Int. J. Mol. Sci. 24, 15500 (2023).","DOI":"10.3390\/ijms242115500"},{"key":"2768_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2017.10","volume":"3","author":"JJ Kathiriya","year":"2017","unstructured":"Kathiriya, J. J. et al. Galectin-1 inhibition attenuates profibrotic signaling in hypoxia-induced pulmonary fibrosis. Cell Death Discov. 3, 17010 (2017).","journal-title":"Cell Death Discov."},{"key":"2768_CR216","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1093\/emboj\/16.17.5353","volume":"16","author":"A Nakao","year":"1997","unstructured":"Nakao, A. et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16, 5353\u20135362 (1997).","journal-title":"EMBO J."},{"key":"2768_CR217","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","volume":"185","author":"AC Mackinnon","year":"2012","unstructured":"Mackinnon, A. C. et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med. 185, 537\u2013546 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2768_CR218","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1073\/pnas.0511167103","volume":"103","author":"NC Henderson","year":"2006","unstructured":"Henderson, N. C. et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. USA 103, 5060\u20135065 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2768_CR219","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","volume":"172","author":"NC Henderson","year":"2008","unstructured":"Henderson, N. C. et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288\u2013298 (2008).","journal-title":"Am. J. Pathol."},{"key":"2768_CR220","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1093\/cvr\/cvad116","volume":"119","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Inhibition of galectin-3 post-infarction impedes progressive fibrosis by regulating inflammatory profibrotic cascades. Cardiovasc Res. 119, 2536\u20132549 (2023).","journal-title":"Cardiovasc Res."},{"key":"2768_CR221","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu, L. et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail 6, 107\u2013117 (2013).","journal-title":"Circ. Heart Fail"},{"key":"2768_CR222","doi-asserted-by":"crossref","unstructured":"Perez-Moreno, E. et al. Endogenous Galectin-8 protects against Th17 infiltration and fibrosis following acute kidney injury. Mol. Med. 31, 192 (2025).","DOI":"10.1186\/s10020-025-01245-y"},{"key":"2768_CR223","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee, H. et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct. Target. Ther. 10, 248 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2768_CR224","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/glycob\/cwy001","volume":"28","author":"P Nangia-Makker","year":"2018","unstructured":"Nangia-Makker, P., Hogan, V. & Raz, A. Galectin-3 and cancer stemness. Glycobiology 28, 172\u2013181 (2018).","journal-title":"Glycobiology"},{"key":"2768_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109647","volume":"36","author":"A Sharanek","year":"2021","unstructured":"Sharanek, A. et al. Transcriptional control of brain tumor stem cells by a carbohydrate binding protein. Cell Rep. 36, 109647 (2021).","journal-title":"Cell Rep."},{"key":"2768_CR226","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1101\/gad.312157.118","volume":"32","author":"PJ Cimino","year":"2018","unstructured":"Cimino, P. J. et al. Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev. 32, 512\u2013523 (2018).","journal-title":"Genes Dev."},{"key":"2768_CR227","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.semcancer.2014.03.004","volume":"27","author":"T Funasaka","year":"2014","unstructured":"Funasaka, T., Raz, A. & Nangia-Makker, P. Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol. 27, 30\u201338 (2014).","journal-title":"Semin Cancer Biol."},{"key":"2768_CR228","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"Fodde, R. & Brabletz, T. Wnt\/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 19, 150\u2013158 (2007).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2768_CR229","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/glycob\/cwv088","volume":"26","author":"HY Kuo","year":"2016","unstructured":"Kuo, H. Y. et al. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer. Glycobiology 26, 155\u2013165 (2016).","journal-title":"Glycobiology"},{"key":"2768_CR230","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41416-024-02621-x","volume":"130","author":"Y Matoba","year":"2024","unstructured":"Matoba, Y. et al. Targeting galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. Br. J. Cancer 130, 1463\u20131476 (2024).","journal-title":"Br. J. Cancer"},{"key":"2768_CR231","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2014.09.012","volume":"355","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4. Cancer Lett. 355, 85\u201395 (2014).","journal-title":"Cancer Lett."},{"key":"2768_CR232","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ncb2953","volume":"16","author":"L Seguin","year":"2014","unstructured":"Seguin, L. et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 16, 457\u2013468 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2768_CR233","doi-asserted-by":"publisher","first-page":"320","DOI":"10.15283\/ijsc20186","volume":"14","author":"Q Guo","year":"2021","unstructured":"Guo, Q. et al. Galectin-3 derived from HucMSC exosomes promoted myocardial fibroblast-to-myofibroblast differentiation associated with beta-catenin upregulation. Int. J. Stem Cells 14, 320\u2013330 (2021).","journal-title":"Int. J. Stem Cells"},{"key":"2768_CR234","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.bone.2009.01.365","volume":"44","author":"T Arikawa","year":"2009","unstructured":"Arikawa, T. et al. Galectin-9 accelerates transforming growth factor beta3-induced differentiation of human mesenchymal stem cells to chondrocytes. Bone 44, 849\u2013857 (2009).","journal-title":"Bone"},{"key":"2768_CR235","doi-asserted-by":"publisher","first-page":"29761","DOI":"10.1074\/jbc.M401303200","volume":"279","author":"RY Yang","year":"2004","unstructured":"Yang, R. Y. et al. Galectin-12 is required for adipogenic signaling and adipocyte differentiation. J. Biol. Chem. 279, 29761\u201329766 (2004).","journal-title":"J. Biol. Chem."},{"key":"2768_CR236","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1189\/jlb.1HI0316-134R","volume":"100","author":"H Xue","year":"2016","unstructured":"Xue, H., Yang, R. Y., Tai, G. & Liu, F. T. Galectin-12 inhibits granulocytic differentiation of human NB4 promyelocytic leukemia cells while promoting lipogenesis. J. Leukoc. Biol. 100, 657\u2013664 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"2768_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.120","volume":"3","author":"EY Huang","year":"2012","unstructured":"Huang, E. Y. et al. A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis. 3, e251 (2012).","journal-title":"Cell Death Dis."},{"key":"2768_CR238","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/glycob\/cwu062","volume":"24","author":"P Kuo","year":"2014","unstructured":"Kuo, P. & Le, Q. T. Galectin-1 links tumor hypoxia and radiotherapy. Glycobiology 24, 921\u2013925 (2014).","journal-title":"Glycobiology"},{"key":"2768_CR239","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/1878-0261.12695","volume":"14","author":"P Gorniak","year":"2020","unstructured":"Gorniak, P. et al. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells. Mol. Oncol. 14, 1817\u20131832 (2020).","journal-title":"Mol. Oncol."},{"key":"2768_CR240","doi-asserted-by":"publisher","first-page":"e70410","DOI":"10.1002\/cam4.70410","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zou, Y., Ye, Y. & Chen, Y. Advances in the understanding of the pathogenesis of triple-negative breast cancer. Cancer Med. 13, e70410 (2024).","journal-title":"Cancer Med."},{"key":"2768_CR241","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","volume":"38","author":"JJ Qin","year":"2019","unstructured":"Qin, J. J., Yan, L., Zhang, J. & Zhang, W. D. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J. Exp. Clin. Cancer Res. 38, 195 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2768_CR242","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-23-2241","volume":"84","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Targeting galectin-1 overcomes paclitaxel resistance in esophageal squamous cell carcinoma. Cancer Res. 84, 3894\u20133908 (2024).","journal-title":"Cancer Res."},{"key":"2768_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101702","volume":"12","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. Galectin-3 in tumor-stromal cells enhances gemcitabine resistance in pancreatic adenocarcinoma by suppressing oxidative phosphorylation. Genes Dis. 12, 101702 (2025).","journal-title":"Genes Dis."},{"key":"2768_CR244","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/1759-7714.14474","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac. Cancer 13, 1961\u20131973 (2022).","journal-title":"Thorac. Cancer"},{"key":"2768_CR245","doi-asserted-by":"crossref","unstructured":"Linghu, D. et al. Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion. J. Immunother. Cancer 13, e010926 (2025).","DOI":"10.1136\/jitc-2024-010926"},{"key":"2768_CR246","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/0008-5472.CAN-08-4153","volume":"69","author":"S Song","year":"2009","unstructured":"Song, S. et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 69, 1343\u20131349 (2009).","journal-title":"Cancer Res."},{"key":"2768_CR247","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s10120-021-01186-5","volume":"24","author":"SJ Kim","year":"2021","unstructured":"Kim, S. J. et al. Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression. Gastric Cancer 24, 1050\u20131062 (2021).","journal-title":"Gastric Cancer"},{"key":"2768_CR248","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2443.2009.01287.x","volume":"14","author":"A Matsuura","year":"2009","unstructured":"Matsuura, A. et al. Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 14, 511\u2013521 (2009).","journal-title":"Genes Cells"},{"key":"2768_CR249","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.7150\/thno.100939","volume":"14","author":"S Zhao","year":"2024","unstructured":"Zhao, S. et al. HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages. Theranostics 14, 7072\u20137087 (2024).","journal-title":"Theranostics"},{"key":"2768_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.148022","volume":"1792","author":"Z Cai","year":"2022","unstructured":"Cai, Z. et al. Association between abnormal expression and methylation of LGALS1 in amyotrophic lateral sclerosis. Brain Res. 1792, 148022 (2022).","journal-title":"Brain Res."},{"key":"2768_CR251","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cam4.2075","volume":"8","author":"X He","year":"2019","unstructured":"He, X., Zhang, S., Chen, J. & Li, D. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma. Cancer Med. 8, 2031\u20132040 (2019).","journal-title":"Cancer Med."},{"key":"2768_CR252","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/2211-5463.12973","volume":"10","author":"E Armenta-Castro","year":"2020","unstructured":"Armenta-Castro, E. et al. Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells. FEBS Open Bio 10, 2305\u20132315 (2020).","journal-title":"FEBS Open Bio"},{"key":"2768_CR253","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2768_CR254","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-32","volume":"11","author":"LG Toussaint III","year":"2012","unstructured":"Toussaint, L. G. III et al. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol. Cancer 11, 32 (2012).","journal-title":"Mol. Cancer"},{"key":"2768_CR255","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4331\/wjbc.v2.i9.193","volume":"2","author":"F Lefranc","year":"2011","unstructured":"Lefranc, F., Mathieu, V. & Kiss, R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J. Biol. Chem. 2, 193\u2013201 (2011).","journal-title":"World J. Biol. Chem."},{"key":"2768_CR256","doi-asserted-by":"crossref","unstructured":"Videla-Richardson, G. A. et al. Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma. Int. J. Mol. Sci. 23, 316 (2021).","DOI":"10.3390\/ijms23010316"},{"key":"2768_CR257","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-18-0157","volume":"24","author":"TC Shih","year":"2018","unstructured":"Shih, T. C. et al. Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion. Clin. Cancer Res. 24, 4319\u20134331 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR258","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/bjc.2013.828","volume":"110","author":"NM White","year":"2014","unstructured":"White, N. M. et al. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF\/mTOR signaling axis. Br. J. Cancer 110, 1250\u20131259 (2014).","journal-title":"Br. J. Cancer"},{"key":"2768_CR259","doi-asserted-by":"crossref","unstructured":"Li, C. H. et al. Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives. Biomedicines 9, 1159 (2021).","DOI":"10.3390\/biomedicines9091159"},{"key":"2768_CR260","doi-asserted-by":"publisher","DOI":"10.2196\/76811","volume":"14","author":"C Mellenthin","year":"2025","unstructured":"Mellenthin, C. et al. IL-6\/GP130\/JAK\/STAT3 Pathway Activation In Pancreatic Ductal Adenocarcinoma And Its Association With Clinical Features: Protocol For A Retrospective Cross-sectional Study. JMIR Res. Protoc. 14, e76811 (2025).","journal-title":"JMIR Res. Protoc."},{"key":"2768_CR261","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/cdd.2017.119","volume":"24","author":"T Piyush","year":"2017","unstructured":"Piyush, T. et al. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death Differ. 24, 1937\u20131947 (2017).","journal-title":"Cell Death Differ."},{"key":"2768_CR262","doi-asserted-by":"publisher","first-page":"29913","DOI":"10.1074\/jbc.M111.226423","volume":"286","author":"AI Markowska","year":"2011","unstructured":"Markowska, A. I., Jefferies, K. C. & Panjwani, N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J. Biol. Chem. 286, 29913\u201329921 (2011).","journal-title":"J. Biol. Chem."},{"key":"2768_CR263","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cytogfr.2021.03.004","volume":"60","author":"N Porebska","year":"2021","unstructured":"Porebska, N. et al. Galectins as modulators of receptor tyrosine kinases signaling in health and disease. Cytokine Growth Factor Rev. 60, 89\u2013106 (2021).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2768_CR264","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41416-020-1022-4","volume":"123","author":"M Song","year":"2020","unstructured":"Song, M. et al. Galectin-3 favours tumour metastasis via the activation of beta-catenin signalling in hepatocellular carcinoma. Br. J. Cancer 123, 1521\u20131534 (2020).","journal-title":"Br. J. Cancer"},{"key":"2768_CR265","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00535-012-0663-3","volume":"48","author":"KL Wu","year":"2013","unstructured":"Wu, K. L. et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1\/2 pathway. J. Gastroenterol. 48, 350\u2013359 (2013).","journal-title":"J. Gastroenterol."},{"key":"2768_CR266","unstructured":"Tzeng, S. F. et al. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer. FASEB J 15, fj201800687 (2018)."},{"key":"2768_CR267","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.1158\/0008-5472.CAN-16-0641","volume":"76","author":"CH Tsai","year":"2016","unstructured":"Tsai, C. H. et al. Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells. Cancer Res. 76, 5756\u20135767 (2016).","journal-title":"Cancer Res."},{"key":"2768_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01218-6","volume":"15","author":"X Teng","year":"2025","unstructured":"Teng, X. et al. Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening. EJNMMI Res. 15, 22 (2025).","journal-title":"EJNMMI Res."},{"key":"2768_CR269","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1158\/0008-5472.CAN-04-0985","volume":"64","author":"S Ueda","year":"2004","unstructured":"Ueda, S., Kuwabara, I. & Liu, F. T. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res. 64, 5672\u20135676 (2004).","journal-title":"Cancer Res."},{"issue":"Pt 13","key":"2768_CR270","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1242\/jcs.113.13.2385","volume":"113","author":"YR Hadari","year":"2000","unstructured":"Hadari, Y. R. et al. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J. Cell Sci. 113(Pt 13), 2385\u20132397 (2000).","journal-title":"J. Cell Sci."},{"key":"2768_CR271","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/gut.50.3.392","volume":"50","author":"N Nagy","year":"2002","unstructured":"Nagy, N. et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50, 392\u2013401 (2002).","journal-title":"Gut"},{"key":"2768_CR272","doi-asserted-by":"publisher","first-page":"7660","DOI":"10.4049\/jimmunol.181.11.7660","volume":"181","author":"K Nagahara","year":"2008","unstructured":"Nagahara, K. et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 181, 7660\u20137669 (2008).","journal-title":"J. Immunol."},{"key":"2768_CR273","doi-asserted-by":"crossref","unstructured":"Chiyo, T. et al. Galectin-9 induces mitochondria-mediated apoptosis of esophageal cancer in vitro and in vivo in a xenograft mouse model. Int. J. Mol. Sci. 20, 2634 (2019).","DOI":"10.3390\/ijms20112634"},{"key":"2768_CR274","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1038\/jid.2012.133","volume":"132","author":"VR Wiersma","year":"2012","unstructured":"Wiersma, V. R. et al. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J. Invest. Dermatol. 132, 2302\u20132305 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"2768_CR275","doi-asserted-by":"publisher","first-page":"1122864","DOI":"10.3389\/fgene.2023.1122864","volume":"14","author":"M Assem","year":"2023","unstructured":"Assem, M. et al. Promoter methylation might shift the balance of Galectin-3 & 12 expression in de novo adult acute myeloid leukemia patients. Front. Genet. 14, 1122864 (2023).","journal-title":"Front. Genet."},{"key":"2768_CR276","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fimmu.2020.00145","volume":"11","author":"L Vokalova","year":"2020","unstructured":"Vokalova, L. et al. Placental protein 13 (galectin-13) polarizes neutrophils toward an immune regulatory phenotype. Front. Immunol. 11, 145 (2020).","journal-title":"Front. Immunol."},{"key":"2768_CR277","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vph.2016.02.006","volume":"81","author":"NW van der Hoeven","year":"2016","unstructured":"van der Hoeven, N. W. et al. The emerging role of galectins in cardiovascular disease. Vasc. Pharm. 81, 31\u201341 (2016).","journal-title":"Vasc. Pharm."},{"key":"2768_CR278","doi-asserted-by":"crossref","unstructured":"Chen, P. Y. et al. Galectin-1 in cardiovascular pathogenesis: unraveling dual roles and mechanistic insights in emerging research. Medicina (Kaunas) 61, 1020 (2025).","DOI":"10.3390\/medicina61061020"},{"key":"2768_CR279","doi-asserted-by":"publisher","first-page":"8696543","DOI":"10.1155\/2018\/8696543","volume":"2018","author":"IM Seropian","year":"2018","unstructured":"Seropian, I. M. et al. Galectin-1 as an emerging mediator of cardiovascular inflammation: mechanisms and therapeutic opportunities. Mediators Inflamm. 2018, 8696543 (2018).","journal-title":"Mediators Inflamm."},{"key":"2768_CR280","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1161\/CIRCULATIONAHA.117.031231","volume":"138","author":"Z Hu","year":"2018","unstructured":"Hu, Z. et al. Regulation of blood pressure by targeting Ca(V)1.2-galectin-1 protein interaction. Circulation 138, 1431\u20131445 (2018).","journal-title":"Circulation"},{"key":"2768_CR281","doi-asserted-by":"crossref","unstructured":"Zaborska, B. et al. The role of galectin-3 in heart failure-The diagnostic, prognostic and therapeutic potential-where do we stand? Int. J. Mol. Sci. 24, 13111 (2023).","DOI":"10.3390\/ijms241713111"},{"key":"2768_CR282","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7150\/thno.22196","volume":"8","author":"N Suthahar","year":"2018","unstructured":"Suthahar, N. et al. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics 8, 593\u2013609 (2018).","journal-title":"Theranostics"},{"key":"2768_CR283","doi-asserted-by":"crossref","unstructured":"Kozak, K. & Zajkowska, M. Association of elevated galectin-4 concentrations with obesity, diabetes, and cardiovascular diseases. Int. J. Mol. Sci. 26, 9402 (2025).","DOI":"10.3390\/ijms26199402"},{"key":"2768_CR284","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12933-024-02274-3","volume":"23","author":"MA Elhadad","year":"2024","unstructured":"Elhadad, M. A. et al. Plasma proteome association with coronary heart disease and carotid intima media thickness: results from the KORA F4 study. Cardiovasc. Diabetol. 23, 181 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"2768_CR285","doi-asserted-by":"crossref","unstructured":"St-Pierre, Y. Towards a better understanding of the relationships between galectin-7, p53 and MMP-9 during cancer progression. Biomolecules 11, 879 (2021).","DOI":"10.3390\/biom11060879"},{"key":"2768_CR286","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/cvr\/cvv128","volume":"106","author":"Y Ma","year":"2015","unstructured":"Ma, Y. et al. Deriving a cardiac ageing signature to reveal MMP-9-dependent inflammatory signalling in senescence. Cardiovasc Res. 106, 421\u2013431 (2015).","journal-title":"Cardiovasc Res."},{"key":"2768_CR287","doi-asserted-by":"publisher","first-page":"H1398","DOI":"10.1152\/ajpheart.00090.2014","volume":"306","author":"A Yabluchanskiy","year":"2014","unstructured":"Yabluchanskiy, A. et al. Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 306, H1398\u2013H1407 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2768_CR288","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2022.11.014","volume":"363","author":"F Krautter","year":"2022","unstructured":"Krautter, F. et al. Galectin-9: a novel promoter of atherosclerosis progression. Atherosclerosis 363, 57\u201368 (2022).","journal-title":"Atherosclerosis"},{"key":"2768_CR289","doi-asserted-by":"crossref","unstructured":"Chaudhary, S. et al. Galectins-potential therapeutic targets for neurodegenerative disorders. Int. J. Mol. Sci. 23, 11012 (2022).","DOI":"10.3390\/ijms231911012"},{"key":"2768_CR290","doi-asserted-by":"crossref","unstructured":"da Rosa, M. M. et al. Alzheimer\u2019s disease: Is there a role for galectins? Eur. J. Pharmacol. 909, 174437 (2021).","DOI":"10.1016\/j.ejphar.2021.174437"},{"key":"2768_CR291","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbi.2019.10.015","volume":"83","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Galectin-1 attenuates neurodegeneration in Parkinson\u2019s disease model by modulating microglial MAPK\/IkappaB\/NFkappaB axis through its carbohydrate-recognition domain. Brain Behav. Immun. 83, 214\u2013225 (2020).","journal-title":"Brain Behav. Immun."},{"key":"2768_CR292","doi-asserted-by":"crossref","unstructured":"Ramos-Martinez, E. et al. Association between galectin levels and neurodegenerative diseases: systematic review and meta-analysis. Biomolecules 12, 1062 (2022).","DOI":"10.3390\/biom12081062"},{"key":"2768_CR293","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1074\/jbc.M117.809293","volume":"293","author":"B Falcon","year":"2018","unstructured":"Falcon, B. et al. Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J. Biol. Chem. 293, 2438\u20132451 (2018).","journal-title":"J. Biol. Chem."},{"key":"2768_CR294","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","volume":"17","author":"R Medeiros","year":"2011","unstructured":"Medeiros, R., Baglietto-Vargas, D. & LaFerla, F. M. The role of tau in Alzheimer\u2019s disease and related disorders. CNS Neurosci. Ther. 17, 514\u2013524 (2011).","journal-title":"CNS Neurosci. Ther."},{"key":"2768_CR295","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05058-3","volume":"13","author":"J Garcia-Revilla","year":"2022","unstructured":"Garcia-Revilla, J. et al. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 13, 628 (2022).","journal-title":"Cell Death Dis."},{"key":"2768_CR296","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4103\/NRR.NRR-D-23-01508","volume":"20","author":"G Zhang","year":"2025","unstructured":"Zhang, G. et al. Infiltration by monocytes of the central nervous system and its role in multiple sclerosis: reflections on therapeutic strategies. Neural Regen. Res. 20, 779\u2013793 (2025).","journal-title":"Neural Regen. Res."},{"key":"2768_CR297","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1046992","volume":"15","author":"Q Peng","year":"2022","unstructured":"Peng, Q. et al. Galectin-9\/Tim-3 pathway mediates dopaminergic neurodegeneration in MPTP-induced mouse model of Parkinson\u2019s disease. Front Mol. Neurosci. 15, 1046992 (2022).","journal-title":"Front Mol. Neurosci."},{"key":"2768_CR298","doi-asserted-by":"publisher","first-page":"105373","DOI":"10.1016\/j.clineuro.2019.105373","volume":"184","author":"T Cengiz","year":"2019","unstructured":"Cengiz, T., Turkboylari, S., Gencler, O. S. & Anlar, O. The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression. Clin. Neurol. Neurosurg. 184, 105373 (2019).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"2768_CR299","doi-asserted-by":"publisher","first-page":"9186940","DOI":"10.1155\/2018\/9186940","volume":"2018","author":"MF Brinchmann","year":"2018","unstructured":"Brinchmann, M. F., Patel, D. M. & Iversen, M. H. The role of galectins as modulators of metabolism and inflammation. Mediators Inflamm. 2018, 9186940 (2018).","journal-title":"Mediators Inflamm."},{"key":"2768_CR300","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","volume":"15","author":"M Kram","year":"2023","unstructured":"Kram, M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J. Hepatol. 15, 201\u2013207 (2023).","journal-title":"World J. Hepatol."},{"key":"2768_CR301","doi-asserted-by":"crossref","unstructured":"Fryk, E., Silva, V. R. R. & Jansson, P. A. Galectin-1 in obesity and type 2 diabetes. Metabolites. 12, 930 (2022).","DOI":"10.3390\/metabo12100930"},{"key":"2768_CR302","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.bone.2023.116884","volume":"176","author":"R Pal","year":"2023","unstructured":"Pal, R. & Bhadada, S. K. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: a narrative review. Bone 176, 116884 (2023).","journal-title":"Bone"},{"key":"2768_CR303","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","volume":"18","author":"VP Singh","year":"2014","unstructured":"Singh, V. P., Bali, A., Singh, N. & Jaggi, A. S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharm. 18, 1\u201314 (2014).","journal-title":"Korean J. Physiol. Pharm."},{"key":"2768_CR304","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1096\/fj.201800555RR","volume":"33","author":"N Al-Obaidi","year":"2019","unstructured":"Al-Obaidi, N. et al. Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes. FASEB J. 33, 373\u2013387 (2019).","journal-title":"FASEB J."},{"key":"2768_CR305","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.molmed.2024.11.006","volume":"31","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q., Zhao, Q. & Li, P. Galectin-3 in metabolic disorders: mechanisms and therapeutic potential. Trends Mol. Med. 31, 424\u2013437 (2025).","journal-title":"Trends Mol. Med."},{"key":"2768_CR306","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12933-022-01690-7","volume":"21","author":"AA Mansour","year":"2022","unstructured":"Mansour, A. A. et al. The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease. Cardiovasc. Diabetol. 21, 253 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"2768_CR307","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509\u2013524 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2768_CR308","doi-asserted-by":"publisher","first-page":"102847","DOI":"10.1016\/j.autrev.2021.102847","volume":"20","author":"WD Xu","year":"2021","unstructured":"Xu, W. D., Huang, Q. & Huang, A. F. Emerging role of galectin family in inflammatory autoimmune diseases. Autoimmun. Rev. 20, 102847 (2021).","journal-title":"Autoimmun. Rev."},{"key":"2768_CR309","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.1128\/JVI.05351-11","volume":"85","author":"C St-Pierre","year":"2011","unstructured":"St-Pierre, C. et al. Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. J. Virol. 85, 11742\u201311751 (2011).","journal-title":"J. Virol."},{"key":"2768_CR310","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1749-6632.2012.06475.x","volume":"1253","author":"S Sato","year":"2012","unstructured":"Sato, S., Ouellet, M., St-Pierre, C. & Tremblay, M. J. Glycans, galectins, and HIV-1 infection. Ann. N. Y Acad. Sci. 1253, 133\u2013148 (2012).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"2768_CR311","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jmii.2019.09.005","volume":"53","author":"WH Wang","year":"2020","unstructured":"Wang, W. H. et al. The role of galectins in virus infection - A systemic literature review. J. Microbiol Immunol. Infect. 53, 925\u2013935 (2020).","journal-title":"J. Microbiol Immunol. Infect."},{"key":"2768_CR312","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/08923973.2024.2384913","volume":"46","author":"X Hui","year":"2024","unstructured":"Hui, X. et al. Galectin-1-producing mesenchymal stem cells restrain the proliferation of T lymphocytes from patients with systemic lupus erythematosus. Immunopharmacol. Immunotoxicol. 46, 618\u2013626 (2024).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"2768_CR313","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","volume":"77","author":"LL van den Hoogen","year":"2018","unstructured":"van den Hoogen, L. L. et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 77, 1810\u20131814 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2768_CR314","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.3389\/fimmu.2018.03057","volume":"9","author":"SP Mendez-Huergo","year":"2018","unstructured":"Mendez-Huergo, S. P. et al. Clinical relevance of galectin-1 and galectin-3 in rheumatoid arthritis patients: differential regulation and correlation with disease activity. Front Immunol. 9, 3057 (2018).","journal-title":"Front Immunol."},{"key":"2768_CR315","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1419676","volume":"15","author":"J Guo","year":"2024","unstructured":"Guo, J. et al. Galectin-9 as an indicator of functional limitations and radiographic joint damage in patients with rheumatoid arthritis. Front. Immunol. 15, 1419676 (2024).","journal-title":"Front. Immunol."},{"key":"2768_CR316","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1016\/j.bmc.2008.06.044","volume":"16","author":"D Giguere","year":"2008","unstructured":"Giguere, D. et al. Synthesis of stable and selective inhibitors of human galectins-1 and -3. Bioorg. Med. Chem. 16, 7811\u20137823 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"2768_CR317","doi-asserted-by":"publisher","first-page":"18973","DOI":"10.1039\/D2RA03163A","volume":"12","author":"S van Klaveren","year":"2022","unstructured":"van Klaveren, S. et al. Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors. RSC Adv. 12, 18973\u201318984 (2022).","journal-title":"RSC Adv."},{"key":"2768_CR318","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1021\/acs.jmedchem.1c01296","volume":"65","author":"K Bum-Erdene","year":"2022","unstructured":"Bum-Erdene, K. et al. Novel selective galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia. J. Med. Chem. 65, 5975\u20135989 (2022).","journal-title":"J. Med. Chem."},{"key":"2768_CR319","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1747-0285.2011.01283.x","volume":"79","author":"PM Collins","year":"2012","unstructured":"Collins, P. M. et al. Taloside inhibitors of galectin-1 and galectin-3. Chem. Biol. Drug Des. 79, 339\u2013346 (2012).","journal-title":"Chem. Biol. Drug Des."},{"key":"2768_CR320","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/cbdd.13348","volume":"92","author":"C Kishor","year":"2018","unstructured":"Kishor, C., Ross, R. L. & Blanchard, H. Lactulose as a novel template for anticancer drug development targeting galectins. Chem. Biol. Drug Des. 92, 1801\u20131808 (2018).","journal-title":"Chem. Biol. Drug Des."},{"key":"2768_CR321","doi-asserted-by":"crossref","unstructured":"Hirani, N. et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 57, 2002559 (2021).","DOI":"10.1183\/13993003.02559-2020"},{"key":"2768_CR322","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-18-2244","volume":"79","author":"L Vuong","year":"2019","unstructured":"Vuong, L. et al. An orally active galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth And Augments Response to PD-L1 blockade. Cancer Res. 79, 1480\u20131492 (2019).","journal-title":"Cancer Res."},{"key":"2768_CR323","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/2211-5463.13088","volume":"11","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer. FEBS Open Bio 11, 911\u2013920 (2021).","journal-title":"FEBS Open Bio"},{"key":"2768_CR324","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/pro.70143","volume":"34","author":"L Newman","year":"2025","unstructured":"Newman, L. & Vaissier Welborn, V. Binding free energy analysis of galectin-3 natural ligands and synthetic inhibitors. Protein Sci. 34, e70143 (2025).","journal-title":"Protein Sci."},{"key":"2768_CR325","unstructured":"Clinicaltrial.be. An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC) (Galecto Biotech AB, 2022)."},{"key":"2768_CR326","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/OncoTherap.v9.i2.50","volume":"9","author":"AC Ornelas","year":"2022","unstructured":"Ornelas, A. C. et al. Anti-cancer pectins and their role in colorectal cancer treatment. Onco. Ther. 9, 43\u201355 (2022).","journal-title":"Onco. Ther."},{"key":"2768_CR327","doi-asserted-by":"publisher","first-page":"117946","DOI":"10.1016\/j.carbpol.2021.117946","volume":"262","author":"OA Patova","year":"2021","unstructured":"Patova, O. A. et al. Xylogalacturonan-enriched pectin from the fruit pulp of Adansonia digitata: structural characterization and antidepressant-like effect. Carbohydr. Polym. 262, 117946 (2021).","journal-title":"Carbohydr. Polym."},{"key":"2768_CR328","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10719-012-9382-5","volume":"29","author":"X Gao","year":"2012","unstructured":"Gao, X. et al. Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3. Glycoconj. J. 29, 159\u2013165 (2012).","journal-title":"Glycoconj. J."},{"key":"2768_CR329","doi-asserted-by":"crossref","unstructured":"Leclere, L., Cutsem, P. V. & Michiels, C. Anti-cancer activities of pH- or heat-modified pectin. Front. Pharmacol. 4, 128 (2013).","DOI":"10.3389\/fphar.2013.00128"},{"key":"2768_CR330","doi-asserted-by":"crossref","unstructured":"de Oliveira, D. P., Todorov, S. D. & Fabi, J. P. Exploring the prebiotic potentials of hydrolyzed pectins: mechanisms of action and gut microbiota modulation. Nutrients. 16, 3689 (2024).","DOI":"10.3390\/nu16213689"},{"key":"2768_CR331","doi-asserted-by":"crossref","unstructured":"Eliaz, I. & Raz, A. Pleiotropic effects of modified citrus pectin. Nutrients. 11, 2619 (2019).","DOI":"10.3390\/nu11112619"},{"key":"2768_CR332","doi-asserted-by":"crossref","unstructured":"Ahmed, R., Anam, K. & Ahmed, H. Development of galectin-3 targeting drugs for therapeutic applications in various diseases. Int. J. Mol. Sci. 24, 8116 (2023).","DOI":"10.3390\/ijms24098116"},{"key":"2768_CR333","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1892265","volume":"10","author":"ER Sturgill","year":"2021","unstructured":"Sturgill, E. R. et al. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology 10, 1892265 (2021).","journal-title":"Oncoimmunology"},{"key":"2768_CR334","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1021\/jm300014q","volume":"55","author":"RP Dings","year":"2012","unstructured":"Dings, R. P. et al. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J. Med. Chem. 55, 5121\u20135129 (2012).","journal-title":"J. Med. Chem."},{"key":"2768_CR335","first-page":"100170","volume":"11","author":"SG Nerella","year":"2024","unstructured":"Nerella, S. G. Non-carbohydrate Galectin-1 inhibitors as promising anticancer agents: design strategies, structure activity relationship and mechanistic insights. Eur. J. Med. Chem. Rep. 11, 100170 (2024).","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"2768_CR336","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0304-3835(03)00015-6","volume":"194","author":"RP Dings","year":"2003","unstructured":"Dings, R. P. et al. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 194, 55\u201366 (2003).","journal-title":"Cancer Lett."},{"key":"2768_CR337","doi-asserted-by":"publisher","first-page":"45746","DOI":"10.1074\/jbc.M308608200","volume":"278","author":"KH Mayo","year":"2003","unstructured":"Mayo, K. H. et al. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J. Biol. Chem. 278, 45746\u201345752 (2003).","journal-title":"J. Biol. Chem."},{"key":"2768_CR338","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-020-09749-3","volume":"24","author":"JM Perez Saez","year":"2021","unstructured":"Perez Saez, J. M. et al. Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities. Angiogenesis 24, 1\u20135 (2021).","journal-title":"Angiogenesis"},{"key":"2768_CR339","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2012-12-474569","volume":"121","author":"J Ouyang","year":"2013","unstructured":"Ouyang, J. et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 121, 3431\u20133433 (2013).","journal-title":"Blood"},{"key":"2768_CR340","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1182\/blood-2006-04-016451","volume":"109","author":"MI Garin","year":"2007","unstructured":"Garin, M. I. et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109, 2058\u20132065 (2007).","journal-title":"Blood"},{"key":"2768_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82686-3","volume":"11","author":"M Stasenko","year":"2021","unstructured":"Stasenko, M. et al. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16\/CA-125-expressing malignancies. Sci. Rep. 11, 3718 (2021).","journal-title":"Sci. Rep."},{"key":"2768_CR342","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1128\/AAC.05595-11","volume":"56","author":"C St-Pierre","year":"2012","unstructured":"St-Pierre, C. et al. Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection. Antimicrob. Agents Chemother. 56, 154\u2013162 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2768_CR343","doi-asserted-by":"crossref","unstructured":"Wdowiak, K. et al. Galectin targeted therapy in oncology: current knowledge and perspectives. Int. J. Mol. Sci. 19, 210 (2018).","DOI":"10.3390\/ijms19010210"},{"key":"2768_CR344","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1111\/j.1742-4658.2010.07764.x","volume":"277","author":"H Sanchez-Ruderisch","year":"2010","unstructured":"Sanchez-Ruderisch, H. et al. Tumor suppressor p16 INK4a: downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J. 277, 3552\u20133563 (2010).","journal-title":"FEBS J."},{"key":"2768_CR345","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158, 1334\u20131345.e1335 (2020).","journal-title":"Gastroenterology"},{"key":"2768_CR346","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong, G., Chang, X., Xie, W. & Zhou, X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct. Target. Ther. 9, 308 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2768_CR347","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2768_CR348","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/lifemedi\/lnac043","volume":"1","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Manipulating autophagic degradation in human diseases: from mechanisms to interventions. Life Med. 1, 120\u2013148 (2022).","journal-title":"Life Med."},{"key":"2768_CR349","doi-asserted-by":"publisher","first-page":"pgaf348","DOI":"10.1093\/pnasnexus\/pgaf348","volume":"4","author":"R Martinez-Carrasco","year":"2025","unstructured":"Martinez-Carrasco, R. & Argueso, P. Single-cell mapping of the glycocalyx in the adult human and mouse ocular surface. PNAS Nexus 4, pgaf348 (2025).","journal-title":"PNAS Nexus"},{"key":"2768_CR350","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.bbadva.2024.100125","volume":"6","author":"S Keisham","year":"2024","unstructured":"Keisham, S. & Tateno, H. Emerging technologies for single-cell glycomics. BBA Adv. 6, 100125 (2024).","journal-title":"BBA Adv."},{"key":"2768_CR351","doi-asserted-by":"publisher","first-page":"e2301338","DOI":"10.1002\/smtd.202301338","volume":"8","author":"S Keisham","year":"2024","unstructured":"Keisham, S., Saito, S., Kowashi, S. & Tateno, H. Droplet-based glycan and RNA sequencing for profiling the distinct cellular glyco-states in single cells. Small Methods 8, e2301338 (2024).","journal-title":"Small Methods"},{"key":"2768_CR352","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1002\/cpz1.777","volume":"3","author":"H Odaka","year":"2023","unstructured":"Odaka, H. & Tateno, H. Single-cell glycan and RNA sequencing (scGR-seq). Curr. Protoc. 3, e777 (2023).","journal-title":"Curr. Protoc."},{"key":"2768_CR353","doi-asserted-by":"publisher","first-page":"102631","DOI":"10.1016\/j.stemcr.2025.102631","volume":"20","author":"H Odaka","year":"2025","unstructured":"Odaka, H. & Tateno, H. Single-cell glycome and transcriptome profiling uncovers the glycan signature of each cell subpopulation of human iPSC-derived neurons. Stem Cell Rep. 20, 102631 (2025).","journal-title":"Stem Cell Rep."},{"key":"2768_CR354","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11658-022-00336-6","volume":"27","author":"S Shojaei Baghini","year":"2022","unstructured":"Shojaei Baghini, S. et al. CRISPR\/Cas9 application in cancer therapy: a pioneering genome editing tool. Cell Mol. Biol. Lett. 27, 35 (2022).","journal-title":"Cell Mol. Biol. Lett."},{"key":"2768_CR355","doi-asserted-by":"crossref","unstructured":"Blazev, R. et al. Integrated glycoproteomics identifies a role of N-glycosylation and galectin-1 on myogenesis and muscle development. Mol. Cell Proteomics 20, 100030 (2021).","DOI":"10.1074\/mcp.RA120.002166"},{"key":"2768_CR356","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.xcrm.2024.101740","volume":"5","author":"Y Du","year":"2024","unstructured":"Du, Y., Ding, X. & Ye, Y. The spatial multi-omics revolution in cancer therapy: Precision redefined. Cell Rep. Med. 5, 101740 (2024).","journal-title":"Cell Rep. Med."},{"key":"2768_CR357","doi-asserted-by":"publisher","first-page":"74","DOI":"10.31083\/j.fbl2804074","volume":"28","author":"J Wei","year":"2023","unstructured":"Wei, J., Wu, Y., Sun, Y. & Chen, D. Galectin-1 regulates RNA expression and alternative splicing of angiogenic genes in HUVECs. Front. Biosci. (Landmark Ed.) 28, 74 (2023).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"2768_CR358","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1091\/mbc.e10-06-0534","volume":"22","author":"C Villeneuve","year":"2011","unstructured":"Villeneuve, C. et al. Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol. Biol. Cell 22, 999\u20131013 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"2768_CR359","unstructured":"ClinicalTrials.gov. Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA (EcoNugenics, 2012)."},{"key":"2768_CR360","unstructured":"ClinicalTrials.gov. Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia (La Jolla Pharmaceutical Company, 2007)."},{"key":"2768_CR361","unstructured":"ClinicalTrials.gov. Phase 1\/2 Study of GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B Cell Lymphoma (La Jolla Pharmaceutical Company, 2008)."},{"key":"2768_CR362","unstructured":"ClinicalTrials.gov. An Open-Label Phase 1\/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed\/Refractory Multiple Myeloma (La Jolla Pharmaceutical Company, 2008)."},{"key":"2768_CR363","unstructured":"ClinicalTrials.gov. A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors (Galectin Therapeutics Inc, 2003)."},{"key":"2768_CR364","unstructured":"ClinicalTrials.gov. Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy (Galectin Therapeutics Inc., 2006)."},{"key":"2768_CR365","unstructured":"ClinicalTrials.gov. A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer (Galectin Therapeutics Inc., 2005)."},{"key":"2768_CR366","unstructured":"ClinicalTrials.gov. Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer (Galectin Therapeutics Inc., 2006)."},{"key":"2768_CR367","unstructured":"ClinicalTrials.gov. Phase I\/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma (Cliniques universitaires Saint-Luc-Universit\u00e9 Catholique de Louvain, 2012)."},{"key":"2768_CR368","unstructured":"ClinicalTrials.gov. Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma (Providence Health & Services, 2015)."},{"key":"2768_CR369","unstructured":"ClinicalTrials.gov. Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma (Providence Health & Services, 2021)."},{"key":"2768_CR370","unstructured":"ClinicalTrials.gov. Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma (Providence Health & Services, 2023)."},{"key":"2768_CR371","unstructured":"ClinicalTrials.gov. Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (Providence Health & Services, 2014)."},{"key":"2768_CR372","unstructured":"ClinicalTrials.gov. A Phase I Study With an Expansion Cohort\/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed\/Refractory Hodgkin Lymphoma (National Cancer Institute (NCI), 2013)."},{"key":"2768_CR373","unstructured":"ClinicalTrials.gov. A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors (Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), 2012)."},{"key":"2768_CR374","unstructured":"ClinicalTrials.gov. A Phase 1\/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors (PureTech, 2020)."},{"key":"2768_CR375","unstructured":"ClinicalTrials.gov. Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission (Northwestern University, 2015)."},{"key":"2768_CR376","unstructured":"ClinicalTrials.gov. A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed\/Refractory Acute Myeloid Leukemia (AML), or With Relapsed\/Refractory, High-risk Myelodysplastic Syndrome (MDS) (PureTech, 2023)."},{"key":"2768_CR377","unstructured":"ClinicalTrials.gov. A Placebo-controlled RCT in HV\u2019s Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF) (Galecto Biotech AB, 2014)."},{"key":"2768_CR378","unstructured":"ClinicalTrials.gov. A Randomized, 52 Week, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor (Galecto Biotech AB, 2019)."},{"key":"2768_CR379","unstructured":"ClinicalTrials.gov. DEFINE\u2014Evaluating Therapies for COVID-19 (University of Edinburgh, 2020)."},{"key":"2768_CR380","unstructured":"ClinicalTrials.gov. GULLIVER-1. A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis (Galecto Biotech AB, 2020)."},{"key":"2768_CR381","unstructured":"ClinicalTrials.gov. GULLIVER-2. A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C) (Galecto Biotech AB, 2021)."},{"key":"2768_CR382","unstructured":"ClinicalTrials.gov. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension (Massachusetts General Hospital, 2013)."},{"key":"2768_CR383","unstructured":"ClinicalTrials.gov. A Phase 1 Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease (La Jolla Pharmaceutical Company, 2012)."},{"key":"2768_CR384","unstructured":"ClinicalTrials.gov. A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease (La Jolla Pharmaceutical Company, 2013)."},{"key":"2768_CR385","unstructured":"ClinicalTrials.gov. A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes (La Jolla Pharmaceutical Company, 2014)."},{"key":"2768_CR386","unstructured":"ClinicalTrials.gov. A Phase 2 Extension Study of Study GCS-100-CS-4002 (La Jolla Pharmaceutical Company, 2014)."},{"key":"2768_CR387","unstructured":"ClinicalTrials.gov. A Phase 2 Extension of Study GCS-100-CS-4003 (La Jolla Pharmaceutical Company, 2014)."},{"key":"2768_CR388","unstructured":"ClinicalTrials.gov. A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) With Advanced Hepatic Fibrosis (Galectin Therapeutics Inc., 2013)."},{"key":"2768_CR389","unstructured":"ClinicalTrials.gov. A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (Galectin Therapeutics Inc., 2015)."},{"key":"2768_CR390","unstructured":"ClinicalTrials.gov. Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis (Galectin Therapeutics Inc., 2015)."},{"key":"2768_CR391","unstructured":"ClinicalTrials.gov. A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis (Galectin Therapeutics Inc., 2015)."},{"key":"2768_CR392","unstructured":"ClinicalTrials.gov. A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment (Galectin Therapeutics Inc., 2020)."},{"key":"2768_CR393","unstructured":"ClinicalTrials.gov. A Seamless, Adaptive, Phase 2b\/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis (Galectin Therapeutics Inc., 2020)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02768-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02768-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02768-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:04:38Z","timestamp":1780679078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02768-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":393,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2768"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02768-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}